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ABSTRACT 
In humans, leishmaniasis comprises a spectrum of disease from cutaneous lesions to 
destructive mucocutaneous erosions or an insidiously progressive fatal visceralising 
disease. An estimated 1 to 1.5 million people are afflicted each year with cutaneous 
leishmaniasis and 500 000 victims succumb to visceral disease per annum world-
wide. Leishmaniasis is caused by protozoan parasites, Leishmania, which are 
transmitted by the phlebotomine sand fly to the host where they become obligate 
intracellular parasites of mononuclear phagocytes. The protozoa are dimorphic. The 
flagellated promastigote (PM) form of the parasite from the sandfly inoculum enters 
the host cell where it transforms into a compact amastigote (AM) without flagellum 
in a parasitophorous vacuole (PV) within 24 hours and replicates by binary fission. 
Whether infection remains asymptomatic or develops into locally aggressive or 
disseminated disease is based in part on parasite type and virulence factors but 
predominantly on the host immune response. 
Cell mediated immunity is required for control of infection following transmission of 
the parasite. This is dependent upon the type of interaction which occurs between the 
antigen presenting cells (APC), the first host cells to encounter the parasite and T 
helper (Th) cells. 
Parallels with human leishmaniasis can be drawn from the murine model of 
Leishmania major infection. In genetically inbred mice there is distinct Th cell 
differentiation, characterised by their cytokine profile, which correlate with 
susceptibility or resistance to disease. The events which direct Th differentiation in 
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susceptible and resistant mouse strains remain controversial but are believed to 
operate in the first hours or days of infection. There is a body of evidence to suggest 
that dendritic cells (DC), the most potent APC, play a role in leishmaniasis. 
However their interaction had only been investigated with AM, not the initial 
infectious PM stage. Whether DC interact with PM and if so, whether this 
interaction plays a significant role in the primary immune response to Leishmania, 
particularly in Th differentiation, is a tantalising but as yet unanswered question. 
Two studies are described in this thesis. The major study involved original 
laboratory research investigating the role of dendritic cells in the pathogenesis of 
leishmaniasis. The supplementary study was a clinical field study undertaken in an 
hyperendemic area for cutaneous leishmaniasis (CL) in Syria to trial a novel topical 
therapy for treatment of CL. 
The major study was based on the development of a murine in-vitro model to 
investigate the hypothesis that DC internalise L.major PM and play a pivotal role in 
the early events that shape the development of a cellular immune response to 
infection. Conditions were defined for optimal DC internalisation of L.major PM 
and their stimulation of naive T cell responses to leishmanial antigens. Their 
potential to influence Th development, by cytolcine production or modulation of co-
stimulator expression, was then investigated. 
The original findings from this research suggest that DC play an important role in 
establishing an early primary T cell response to L.major PM. DC internalise L.major 
PM with maximal expression of co-stimulatory and MHC Class II molecules and in 
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response produce IL-12. Combined with results of the primary stimulation assays 
these findings suggest that DC from both susceptible and resistant mouse strains are 
able to stimulate autologous naive T cells when pulsed with PM antigens and provide 
a cytokine environment predicted to favour the development of a Th 1 response. The 
importance of DC in the overall immune response to Leishmania is further 
underlined by observations that macrophages appear to be temporarily paralysed 
during infection with L.major PM, particularly in their production of IL-12, due to a 
number of evasion strategies which the parasite has evolved. This work also 
identifies a potential use of DC in the search of non-peptide antigens shed by L. major 
which are presented via non-classical MHC pathways, as potential vaccine 
candidates. 
The supplementary study involved the development and clinical study of a nitric 
oxide (NO) generating cream in the topical treatment of CL. CL often has a 
protracted period of healing, for months and occasionally years, with potential for 
secondary bacterial infection and significant disfigurement. Current first line 
treatment entails repeated intralesional injections which are painful, time consuming, 
expensive and now associated with increasing parasite resistance. Improvement in 
treatment is greatly needed. 
Nitric oxide synthesised by macrophages is lethal to Leishmania. Since NO diffuses 
into tissues, we reasoned that NO-generating creams applied topically to lesions 
might be an effective and inexpensive treatment for CL. The theory that NO can be 
generated non-enzymatically by the acidification of nitrite (KNO2) by a weak acid 
such as ascorbic acid (ASC), potassium chloride (KCL) or salicylic acid (SAL). 
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Initial laboratory experiments performed by colleagues demonstrated efficacy of this 
topical combination therapy in vitro and in mice. We designed the clinical study to 
trial the nitrite cream in combination with one of the three weak acids for four weeks 
in 40 patients with CL in Aleppo, Syria, and assess clinical responses. Only 11(28%) 
of 40 patients showed improvement and only 5 (12%) of 40 were cured at 2 months. 
The investigation was small but demonstrated reasonably good patient tolerability 
and ease of application. Given the results of this study, and the urgent need for new, 
more easily applicable therapy, further development of NO-generating creams is 
warranted with assessment in placebo-controlled randomised trials. 
Both studies have been published in good peer-reviewed journals advancing 
scientific knowledge in both pathogenesis and treatment of leishmaniasis. Both areas 
are inevitably linked and advances made in the former will hasten the development 
and refinement of much needed treatments and ultimately, prevention of disease. 
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CHAPTER 1 
BACKGROUND AND AIMS 
BACKGROUND AND AIMS 
1.1 	Overview 
Leishmaniasis is predominantly a zoonosis occurring in tropical and sub-tropical 
regions, encompassing a range of clinical syndromes. The diseases caused by the 
protozoan parasite, Leishmania were described in antiquity (Peters and Killick-
Kendrick 1987). The "Balkh sore" was the name given to cutaneous Leishmania 
lesions in Central Asia as early as the first century AD. Medieval Moslem scholars 
referred to it as the "oriental sore" in 15th century records. The parasite was first 
isolated by Leishman (a Scotsman) in 1903 post-mortem from the spleens of British 
soldiers in India who succumbed to an idiopathic febrile illness. He recognised their 
morphological similarity to trypanosomes. In the same year Donovan described the 
characteristic intracellular parasitic forms, later named Leishman-Donovan bodies, 
from the splenic aspirate of a patient. The phlebotomine sandfly was subsequently 
identified as the insect vector in 1942 (reviewed by Peters and Killick-Kendrick 
1987). 
The past three decades has witnessed an escalating interest in Leishmaniasis. World 
Health Organisation (WHO) included it as one of the six items in the UNDP/World 
Bank/WHO Special Program for Research and Training in Tropical Diseases in 
1976. An estimated 1 to 1.5 million people are afflicted each year with cutaneous 
Leishmaniasis and 500 000 victims succumb to visceral disease per annum world-
wide (Desjeux 1996). There is an increasing incidence of leishmaniasis with major 
epidemics occurring in India (Addy and Nandy 1992), Bangladesh (Elias, et al 1989), 
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Sudan (Seaman, et al 1996) and Brazil (Jeronimo, et al 1994). Visceral leishmaniasis 
is emerging as an opportunistic pathogen in conditions where cell mediated 
immunity is compromised such as HIV infection (Alvar, et al 1997) and organ 
transplantation (Berenguer, et al 1998). Leishmaniasis is an increasing threat to non-
immune travellers and military personnel in regions of endemicity (Magill, et al 
1993). 
The treatment of visceral leishmaniasis is less than ideal. The limited drugs available 
have significant toxicity and high failure relates due to parasite resistance and 
persistence (reviewed by Davidson and Konecny 1995, Berman JD 1997). There is 
an urgent need for better understanding of the parasite and its interaction with the 
host's defence system for improved control and management of diseases caused by 
Leishmania. 
In humans, leishmaniasis comprises a spectrum of disease from cutaneous lesions to 
destructive mucocutaneous erosions or an insidiously progressive and often fatal 
visceralising disease (reviewed by Sacks, et al 1993). The phlebotomine sandfly 
transmits the parasite between mammalian hosts. Leishmania are dimorphic 
protozoa. The flagellated promastigote (PM) form of the parasite from the sandfly 
inoculum enters the host cell where it becomes an obligate intracellular parasite of 
mononuclear phagocytes. It transforms into a compact amastigote (AM) without 
flagellum in a parasitophorous vacuole in the host cell within 24 hours and replicates 
by binary fission: Whether infection remains asymptomatic or develops into locally 
aggressive or disseminated disease is based in part on parasite virulence factors but 
mainly on the host immune response (Reiner and Locksley 1995). 
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Cell mediated immunity is required for control of infection following transmission of 
the parasite. This is dependent upon the type of interaction which occurs between the 
antigen presenting cells (APC), the first host cells to encounter the parasite and T 
helper (Th) cells. Parallels with human leislunaniasis can be drawn from the murine 
model of Leishmania major infection (Reiner and Locksley 1994). Indeed, major 
advances in immunological research into host resistance and susceptibility to disease 
have occurred in the past decade using this model (reviewed by Locksley, et al 
1999). In genetically inbred mice there is distinct differentiation of specific Th cells, 
characterised by their cytokine profile, which correlate with susceptibility or 
resistance to Leishmania infection. The events which direct Th differentiation in 
• susceptible and resistant mouse strains remain controversial but are considered to 
operate in the first hours to days following infection (Launois, et al 1997). 
Until recently there was a dearth of knowledge of the type of host cell which initially 
encounters the leishmanial parasite and provides the bridge between the innate and 
acquired immune response. Dendritic cells (DC) are highly potent APC which are 
essential for initiating a cellular immune response. A growing body of evidence 
suggests DC have a major role in the host response to intracellular pathogens 
(reviewed by Reis e Sousa, et al 1999). During natural infection, one of the earliest 
interactions with the host immune system will be between sandfly-transmitted PM 
and cells resident in skin. Initial work found dermal macrophages remained 
relatively inert upon infection with PM (Locksley, et al 1988). Macrophages have 
little respiratory oxidative burst and the usual production of cytokines required for 
intracellular killing and activation of the cellular immune response, particularly 
interleukin-12 (IL-12), is inhibited due to a number of evasion strategies which the 
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parasite has evolved (Reiner, et al 1994; Carrera, et al 1996). Cells of the DC lineage 
including Langerhans' cells (LC) in the epidermis and dermal DC were alternative 
contenders for Leishmania parasitism. To date LC have been shown to take up 
L.major AM and effectively stimulate Leishmania-specific T cell responses (Moll, et 
al 1995). However, minimal uptake of PM by LC was observed in their study. 
Whether dermal DC interact with Leishmania PM and influence naïve Th 
differentiation at the initial stage of infection, was considered a crucial question 
requiring clarification. 
A murine in vitro model was therefore developed to investigate the hypothesis that 
DC internalise L.major PM and play a pivotal role in the early events that shape the 
development of a cellular immune response to Leishmania infection. The 
development of this in vitro model was undertaken by the author as a pilot project 
under the supervision of Professor Stella Knight and Dr Andrew Stagg in the Antigen 
Presentation Research Group and Dr Robert Davidson, Department of Infection and 
Tropical Medicine, Northwick Park Hospital, Harrow. This work was successful in 
attracting funding from the Wellcome Trust to continue With the research for a two 
year period, the results of which form the basis of this thesis. 
Conditions were defined for optimal DC internalisation of L.major PM. The potential 
for Leishmania exposed DC to influence Th development was then investigated with 
primary stimulation assays and measurement of cytokine production and 
costimulator expression. The potential role of a recently characterised DC receptor, 
DEC-205 (Jiang, et al 1995), homologous to the mannose receptor macrophages use 
to endocytose Leishmania PM, was also studied in the DC uptake of L.major PM. 
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Soluble L.major antigen was further purified from culture supernatants to determine 
whether non-peptide antigens could be presented by DC via recently described non-
classical pathways, employing CD1 presentation and stimulation of naive T cell 
responses (Porcelli, et al 1992). 
The findings from this research suggest that DC play an important role in 
establishing an early primary T cell response to L.major PM. DC internalising 
L.major maximally express costimulatory and MHC Class II molecules and 
produce IL-12. Combined with results of the primary stimulation assays, these 
findings suggest that DC from both susceptible and resistant mouse strains are 
able to stimulate autologous naive T cells when pulsed with L.major PM and 
L.major antigens from PM cultures and provide a cytokine environment predicted 
to favour the development of a Thl response. Further, semi-purified, non-peptide 
Lmajor PM antigen was capable of stimulating naive T cell proliferation when 
presented by DC. This work also identifies a potential role for DC in the search 
for non-peptide antigens shed by L.major which are presented via non-classical 
MHC pathways. These may provide potential antigens for vaccine development. 
1.2 Leishmania — the parasite 
1.2.1 Life cycle 
Leishmania are dimorphic protozoa, existing as extracellular, motile, 10-15pm 
flagellated PM at 25°C in the gut of the female phlebotomine sandfly and as 2-31.tm 
intracellular AM without exteriorised flagellum in cells of reticuloendothelial origin 
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in humans and other susceptible mammals. The PM has a major surface 
glycoconjugate, lipophosphoglycan (LPG), which constitutes a dense glycocalyx that 
covers the entire surface of the parasite including the flagellum (Handrnan and 
Goding 1985). As the PM matures in the insect midgut, the structure of the LPG 
undergoes modification enabling the mature forms, termed metacyclics, to migrate to 
the sandfly proboscis for transmission (Fig 1.1). In addition to the role LPG play in 
macrophage attachment discussed below, it is immunogenic for host protective 
responses (Moll and Rollinghoff 1991) and has been identified as a virulence factor 
using LPG1 knock-out mice (Spath, et al 2000). 
The sandfly feeds on pooled blood arising from repeated skin probing and highly 
infectious PM which occlude the proboscis of the feeding sandfly are left in the 
dermis. PM in the tissue spaces activate complement via the alternate pathway by 
binding C3b, forming C3a, C5a and other chemotaxins for monocytes in the 
inflammatory exudate (Brittingharn and Mosser 1996). 1 The elongated, altered LPG 
on metacyclic PM confers resistance to complement-mediated lysis by virtue of the 
dense glycocalyx forcing C5b-9 membrane attack complex formation to occur too far 
from the surface to allow insertion into the parasite membrane (Peuntes, et al 1990). 
Another parasite surface glycoprotein, gp63, a membrane protease also protects the 
PM by cleaving C3b to a form that cannot fix the membrane attack complex 
(Brittingham and Mosser, 1996). Phagocytosis of PM by macrophages involves 
recognition of specific parasite ligands by receptors on the macrophage surface. LPG 
fixes predominantly C3b, facilitating phagocytosis of PM by macrophages via the 
complement receptor CR1 (Da Silva, et al 1989). By internalising via CR1 and CR3 
I In humans, the major mechanism for PM invasion appears to be through the engagement of CR1 
on erythrocytes and the classical complement pathway (Dominguez and Torana 1999). 
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Fig1.1 Developmental cycle of Leishmania. In mammalian hosts, metacyclic PM 
transmitted by sandfly bite are internalised by macrophages. Intracellular 
development from PM to AM occurs within the phagolysosome. AM replicate 
within the macrophage until cell rupture occurs and released AM attach to recruited 
macrophages to persist within the host. AM within cells or from ruptured cells are 
internalised during sandfly feeding on the host. In the sandfly vector procyclic forms 
develop in the midgut and transform into metacyclic forms as they migrate into the 
proboscis. 
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macrophage receptors, which do not trigger the respiratory burst, parasite survival is 
enhanced. LPG also protects the PM by scavenging hydroxyl radicals and superoxide 
ions normally released upon activation of NADPH oxidase by phagoctyosis (Bogdan 
and Rollinghoff 1999). 
Other parasite surface glycoproteins, such as gp63 (Russell and Wilhelm 1986) and 
additional macrophage receptors such as CR3, the mannose-fucose receptor (Wilson 
and Pearson 1988), the Fc receptor, the fibronectin receptor (Wyler, et al 1995) and 
the receptor for advanced glycosylation end products (Mosser, et al 1987) may also 
play a role in parasite internalisation. Phagocytosis then occurs by one of the 
following mechanisms. Classical 'zipper-like' phagocytosis occurs when. a 
pseudopod extends from the surface membrane and engulfs the particle by advancing 
along the edge like a zipper. A more recently described process of complex 
pseudopodia coiling and stacking, termed 'coiling phagocytosis' directs the organism 
to cytoplasmic compartments (Bogdan and Rollinghoff 1999). 
Components of sandfly saliva may enhance infectivity, predominantly by inhibiting 
macrophage -function, but are not necessary to establish infection in the host 
(reviewed by Solbech and Laskay 2000). 
Following attachment to the macrophage, the PM are rapidly phagocytosed and 
reside in parasitophorous vacuoles which then fuse with secondary lysosomes to 
form a phagolysosome (Sacks, et al 1993). The PM shed their LPG coat, lose their 
flagellum and roundup into 2-3pm AM forms. 
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The AM able to survive lysosomal enzyme attack and low pH replicate in the 
phagolysosome by binary fission until the burgeoning macrophage ruptures allowing 
the spread of the AM to adjacent macrophages which have been recruited to the site 
by the inflammatory response. Uptake of AM by macrophages is more efficient than 
PM internalisation and appears to occur primarily through macrophage FcR and CR3 
receptors (Guy and Belosevic 1993) and heparan sulfate proteoglycans (Love, et al 
1993). By entering either macrophages of the reticuloendothelial organs or of the 
skin where they continue to divide, AM are thus responsible for maintaining and 
spreading infection within the host. Ingestion of infected macrophages from the 
circulation or skin by the feeding phlebotomine sandfly completes the life cycle (Fig 
1.1). 
Sandflies of the genus Lutzomyia transmit leishmaniasis in the Americas and 
Phlebotomus transmit leishmaniasis elsewhere (Peters and Killick-Kendrick 1987). 
Mammalian reservoirs, depending on Leishmania species and geographical location 
are predominantly primate, canine and rodent species. Man is an incidental host, but 
may also serve as a reservoir as occurs in India where there is extensive human 
cutaneous disease. In the Old World, sandfly breeding requires an arid warm 
environment where larvae grow in the cool humid microclimate of cracks and 
crevices in the walls of dwellings or rodent burrows. Cases typically occur in dry, 
rocky hill country where the particular mammalian reservoirs, such as the gerbil and 
domestic dog live in close proximity to man. In the New World, sandfly larvae 
prefer the leaf mould of the forest floor and forest rodents and incidental forest 
visitors are the mammalian host (Peters and Killick-Kendrick 1987). 
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1.2.2 Classification 
The parasite species is difficult to determine microscopically. There is no defined 
sexual stage so traditional criteria for species identification cannot be applied. 
Speciation was originally based on the pattern of human disease caused by the 
parasite, its geographic distribution, specific animal reservoirs and species of sandfly 
vector. Assays using isoenzyme electrophoresis, species-specific monoclonal 
antibodies, restriction endonuclease digestion of kinetoplast DNA (kDNA) and 
species-specific hybridisation with IcDNA probes (reviewed by Pearson, et al 2000) 
have enabled more accurate speciation creating a taxonomy currently in a state of 
flux. 
For practical purposes, the major syndromes of visceral, cutaneous, and 
mucocutaneous Leishmaniasis are divided into Old World and New World and 
attributed to the corresponding , species (Table 1.1). In brief, visceral leishmaniasis 
(VL) is caused by L.donovani in the Old World, L.infantum in the Mediterranean 
littoral, and L.chagasi and L.amazonensis in the New World. L. major and L.tropica 
are the commonest cause of cutaneous leishmaniasis in the Old World and 
Lmexicana and L.braziliensis in the New World. Mucocutaneous disease occurs 
only in the New World and is caused by Lbraziliensis (Lainson and Shaw 1987). 
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Table1.1 Leishmania taxonomic table (adapted from Lainson and Shaw, 1987) 
Disease 	• 	. Species 	Geographical distribution 
Old World 
Visceral leishmaniasis 	L.donovani 	Indian subcontinent, N&E.China, Pakistan, Nepal, E.Africa 
L.infantum 	Middle East, Mediterranean littoral, Balkans, 
C&SW.Asia, N&W.China, N& sub-Saharan Africa 
L.chagasi 	Latin America 
L.amazonensis 	Brazil 
L.tropica (rare) 	Middle East, Saudi Arabia, India, C&WAsia, N.Africa 
Pakistan, Mediterranean littoral 
L.spp 	Kenya, Ethiopia, Sudan, Somalia 
Post-kala-azar dermal 	L.donovani 	Indian subcontinent 
leishmaniasis (PKDL) 
Cutaneous leishmaniasis L.major 	Middle East, India, Pakistan, N&W.China 
L.tropica 	Mediterranean littoral, Middle East, N.Africa, India, Pakistan, 
C&W. Asia 
L.aethiopica 	Ethiopian highlands, Kenya, Yemen 
L.infantum 	Middle East, Mediterranean, C.Asia, N&W.China, 
N.&sub-saharan Africa 
L.donovani 	E.Africa 
Diffuse cutaneous 	L.aethiopica 	Ethiopian highlands, Kenya, Yemen 
leishmaniasis (DCL) 
New World 
Cutaneous leishmaniasis L.mexicana 	C&S.America, Texas 
L.amazonensis Amazon basin, Brazil 
L.pifanoi 	Venezuela 
L.garnhami 	Venezuela 
L.venezuelensis Venezuela 
L. braziliensis 	C&S.America 
L.guyanensis 	Guyana, Surinam, N.Amazon basin 
L.peniviana 	Peru 
L.panamensis 	Panama, Costa Rica, Colombia 
L.colombiensis Colombia, Panama 
L.chagasi 	C&S.America 
Diffuse cutaneous 	L.amazonensis Amazon basin, Brazil 
leishmaniasis 	 L.pifanoi 	Venezuela 
L.mexicana 	C&S.America, Texas 
L.spp 	Dominican Republic 
Mucosal leishmaniasis 	L.brazdiensis 	C&S.America 
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1.3 Leishmaniasis — human disease 
1.3.1 Clinical 
The clinical manifestations of leishmaniasis depend on the species and virulence 
factors of Leishmania and host immune responses, which are partly genetically 
determined. 
Visceral leishmaniasis is the clinical syndrome where the parasites phagocytosed by 
macrophages in the skin eventually disseminate to the mononuclear phagocytes 
throughout the reticuloendothelial system resulting in hepatosplenomegaly, bone 
marrow failure and often death (Fig 1.2). The term kala-azar or black sickness 
derives from the characteristic deepening skin pigmentation in those with dark skin. 
The original inoculation site usually goes unnoticed or bears a transient papule. The 
spleen becomes massively enlarged as splenic lymphoid follicles are replaced by 
parasitised mononuclear cells and Kupffer cells in the liver expand in size and 
frequency many of them containing AM. Diagnosis is usually confirmed with direct 
smear and Geimsa stain of splenic or bone marrow aspirate (Fig 1.3). 
In cutaneous disease a papule forms, enlarges and eventually ulcerates at the 
inoculation site on exposed areas of the body. The incubation period may vary from 
weeks to months or even years. The Old World cutaneous ulcers are generally benign 
with morphology dependent on the parasite responsible. L.tropica is usually urban 
with smaller, single, drier ulcers while L. major occurs in more rural locales and the 
"wet" lesions are usually larger and more ulcerative (Fig 1.4). 
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Fig 1.2. An African patient infected with L.donovani with typical features of kala-
azar, massive splenomegaly, wasting and hyperpigmentation. (Photograph courtesy 
of Dr R.N. Davidson) 
Fig 1.3. Geimsa stain of a bone marrow aspirate from a L.donovani infected patient 
with VL. Macrophages are packed with AM and rupture easily on slide preparation. 
The AM display typical "dot-dash" appearance (arrow) of the kinetoplast (dot) and 
nucleus (dash). 
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In New World CL, L.braziliensis and L.mexicana also cause large, moist ulcers 
usually in rural or forest workers. All ulcers are typically painless, full skin 
thickness with a rolled edge and bed of granulation tissue. They heal spontaneously, 
usually within a year, leaving a papery, depigmented, depressed, burn-like scar 
(Pearson, et al 2000). 
In a subgroup of people, L.braziliensis leads to subsequent destructive facial 
mucocutaneous disease months to years after the cutaneous ulcer has healed. The soft 
and cartilaginous tissues of the nose, palate and upper pharynx are eroded as a result 
of metastatic spread of the parasite following a primary cutaneous ulcer at a distant 
site. This condition termed espundia is often erosive and disfiguring and may lead, to 
death through secondary bacterial infection (Fig 1.5). 
The species are not restricted to causing either cutaneous, mucocutaneous or visceral 
disease. Different strains of L.infantum called L.infantum variants or zymodemes 
may cause cutaneous or mucocutaneous lesions rather than kala-azar (Ben-Ismail, et 
al 1992). L.tropica caused viscerotropic disease in American military personnel 
during the Gulf War (Magill, et al 1993). L.donovani may cause extensive cutaneous 
disease referred to as post-kala-azar dermal leishmaniasis (PKDL) following 
treatment of VL. In this condition multiple nodules, some containing parasites, 
appear over the body surface within a few years of apparent cure of VL. A rarer 
condition called diffuse cutaneous leishmaniasis (DCL) may complicate cutaneous 
ulceration, with multiple skin nodules over face and extremities teeming with 
parasites (Fig 1.6.A). Leishmaniasis recidivans is another disfiguring form of CL 
with satellite non- 
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Fig 1.4 Typical large, moist ulcer of L.major occurring on an exposed area of a 
Syrian man living on the outskirts of Aleppo. 
Fig 1.5 A Brazilian rubber plantation worker infected with L.braziliensis has the 
severely disfiguring mucocutaneous facial erosions referred to as espundia. 
(Photograph courtesy of Dr R N. Davidson.) 
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Fig 1.6 A. An Ethiopian woman with diffuse cutaneous leishmaniasis (DCL) poorly 
responsive to therapy. (Photograph courtesy of Dr R.N.Davidson.) B. A young 
Syrian woman with leishmania recidivans affecting her arm and face who has 
undergone treatment with intralesional injections for 4 years. The lesion has a typical 
healing centre with satellite nodules. 
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ulcerative nodules around a healing centre which may take up to 20 years to resolve 
(Fig 1.6.B). 
Interestingly, DCL resembles the lepromatous form of leprosy where the immune 
response is defective in containing parasites and massive numbers are found in 
lesions. Whereas PICDL and leishmaniasis recidivans reflect the tuberculoid end of 
the spectrum being a parasite-poor hyperergic variant of CL. The 
immunopathogenesis of these conditions are discussed in more detail below. 
1.3.2 Host defence 
Cell-mediated immunity plays a greater role than the humoral immune response in 
Leishmania infection. Cure of leishrnaniasis correlates with the development of 
specific delayed type hypersensitivity (DTH), a proliferative lymphocyte response to 
Leishmania antigen and generally a life-long immunity to rechallenge with the same 
parasite (reviewed by Sacks, et al 1993). Ace the non-self curing end of the spectrum, 
VL is characterised by widespread dissemination of the parasite in the host's 
reticuloendothelial system with absent or reduced generalised DTH and T cell 
proliferative response. DCL which manifest as discrete nodules disseminated over 
the face and extremities is characterised by a loss of specific DTH and lymphocyte 
responsiveness to Leishmania antigen. In this condition the parasites proliferate and 
disseminate unchecked by the host's immune system. 'Cure of VL and DCL 
correlates with the restoration of DTH and lymphocyte responsiveness in-vitro. T 
cell function plays a central role in determining the host immune response to 
infection with Leishmania as outlined further below. 
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VL and DCL are characterised by absence of T cell interferon-y (IFN—y) and 
interleukin-2 (IL-2) production in response to Leishmania antigen in-vitro 
(Carvalho, et al 1985). Macrophages infected with Leishmania have decreased 
capacity to express major histocompatibility complex class II (MHC) (Reiner, et al 
1988) and to produce IL-1 (Ho, et al 1992). Natural killer (NK) cell activity is also 
deficient in VL patients (Harms, et al 1991). An excess of IL-4 in sera And IL-I0 
from bone marrow cells (Karp, et al 1993) has also been detected in patients with 
VL. Furthermore neutralising antibodies to IL-10 and to IL-4 restores T cell 
proliferation and IFN—y production in-vitro (Carvalho, et al 1994). Similarly, IL-12 
can restore T cell responses to Leishmania in vitro from peripheral blood 
mononuclear cells (PBMC) of VL patients (Bacellar, et al 1996). These cytoldnes 
and their interactions are discussed in more detail below, but suffice to say that clear 
differences in T cell function occur in the various forms of human leishmaniasis. 
L.major antigen has been detected in APC in the skin lesions and draining lymph 
nodes of patients suffering from CL (Elhassan, eta! 1994). The involvement of APC 
and specific T cell responses, characterised by their cytolcine profiles, are closely 
reflected in the experimental murine model of leishmaniasis which provides the 
opportunity for more detailed analysis of host response to infection with Leishmania. 
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1.4 Leishmaniasis - Murine Model 
The murine model of leishmaniasis correlates well with human disease and has 
enabled major advances in the study of the immune response to this infection in the 
past two decades (Reiner and Locksley 1994). Although certain factors may 
influence the outcome of infection, such as the parasite strain, dose and site of 
inoculation, host sex, pregnancy and acquired immunosuppression, the most 
important factor is that of genetically determined host predisposition (reviewed by 
Blackwell 1996). A genetic locus for susceptibility to Lmajor (Sc1-1) has been 
mapped to a region of mouse chromosome 11, which contains several candidate 
genes known to affect leishmanial infections (such as those encoding for iNOS, IL-4, 
interferon-regulatory-factor-1, small cytokine family and putative IL-12 response 
gene). Other potential loci for susceptibility have also been identified on 
chromosome 10 and 17 and are being characterised (Lipoldova M et al 2000). Using 
the mouse L.major model, it is appropriate to first outline what is understood of the 
innate immune response prior to exploring the acquired immune response. 
1.4.1 Macrophages 
Macrophages are the host cell in which Leishmania readily replicate. PM evading 
the parasiticidal activity of macrophages transform into AM. The AM stage has 
evolved various mechanisms to enhance survival. AM selectively and actively 
sequestrate and degrade MHC class II antigens (Antoine, et al 1998). AM 
metabolism is adapted to the acidic environment of the parasitophorous vacuole 
(Zilberstien and Shapira 1994). Structural surface proteins and glycolipids appear to 
20 
render AM less susceptible to proteolysis and hydrolysis (reviewed by Handman 
1999). Another mechanism for parasite persistence involves inhibition of apoptosis 
through induction of 'pro-survival' cytokines such as GM-CSF, TNF-a and IL-6, 
thus prolonging the life of the host cell (Moore and Matlashewski 1994). 
1.4.2 IFN-y 
Macrophage activation by T cell derived cytokines is required to contain infection. 
Both scid and nude mice succumb to infection unless T cell reconstituted (Mitchell 
1983; Holaday, et al 1991). IFN-y is one of the cytokines of critical importance. 
Resistant strains of mice have been rendered susceptible to fatal disease progression 
by targeted disruption of either the IFN—y or the IFN—y receptor gene. Recombinant 
IFN-y has enabled clearance of L.major from infected macrophages from susceptible 
mice in-vitro (reviewed by Reiner and Locksley, 1995). 
The parasiticidal effect of IFN—y is primarily mediated through its positive influence 
on macrophage production of nitric oxide (NO) as demonstrated in Fig. 1.7. The 
final step in elimination of the parasite is mediated by NO. Macrophages treated 
with NO inhibitors are unable to restrict L.major replication in vitro and resistant 
mice are unable to control infection in vivo when given NO inhibitors (Liew, et al 
1990). The macrophages of IFN—y and IFN—y receptor gene knock out mice are 
unable to produce NO. IFN-y activates macrophage inducible nitric oxide synthase 
production (iNOS) to catalyse the oxidation of L—otrginine to NO (Fig 1.7) and it is 
the only cytokine independently capable of doing this (Stenger, et al 1994). 
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Fig 1.7 Schematic representation of macrophage processing of Leishmania. The PM 
is taken up by macrophages at initial host infection and transforms into an AM stage 
within a parasitophorous vacuole (PV). The final pathway for parasite killing is 
mediated by NO produced from iNOS oxidation of L-arginine. The predominant 
macrophage activating cytokines are IFNI , and TNF-a produced by T cells and NK 
cells. IL-4 and TGF-13 are important T cell derived inhibitory cytokines. The infected 
macrophages produce IL-10 which enhance T cell production of the inhibitory 
cytokines in the murine model. PM infection of the macrophage suppresses IL-12 
secretion. 
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Other cytokines synergise with IFN—y in NO production. TNF—a, in particular, can 
ameliorate disease in susceptible mice when administered in recombinant form 
(Titus, et al 1989). Neutralising anti-TNF antibody transiently exacerbated disease in 
resistant mice strains while minimally affecting the course of infection in BALB/c 
mice. Disruption of the p55 TNF receptor, which transduces the TNF—a response, , in 
a genetically resistant background developed a persistent low-level infection with 
L.major that was, however, different to that which occurred in either the BALB/c 
mice or IFN—y deficient mice. Other cytokines which also synergise with IFN—y to 
activate macrophages, probably by sharing the IL-2 receptor y chain, include IL-2, 
IL-4 and IL-7 (reviewed by Reiner and Locksley, 1995). 
Transforming growth factor beta (TGF-f3) on the other hand is a potent inhibitor of 
iNOS. TGF—p is prominent in non-healing lesions in susceptible mice and 
conversely is lacking in lesions and draining lymph nodes in resistant mice where it 
was inversely associated with iNOS production (Stenger, et al 1994). Another 
family of cytolcines, IL-3, IL-5 and GM-CSF, which share a common signal-
transducing molecule, also exacerbate L.major infection in vitro and in vivo 
(reviewed by Reiner and Locksley, 1995). 
Once the parasite is degraded in lysosomes, antigen reappears at the cell surface as 
processed peptide associated with MHC class II molecules which can then be 
recognised by the T cell receptor (TCR) on primed CD4+ T cells. The intracellular 
events which take place after endocytosis are gradually being characterised. Within 
minutes of phagoctyosis, Leishmania are found in phagosomal compartments which 
mature and fuse with endocytic organelles to form a parasitophorous vacuole (PV) 
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containing lysosomal hydrolases, cathepsins and 13-glucuronidase (Lang, et al 1994). 
A series of events occur within the PV such that it matures with time into a late 
endosomal compartment bearing lysosomal-associated membrane proteins LAMP-1 
and LAMP-2 in addition to other markers. MHC class II molecules are acquired by 
the PV within 5-24 hours (Lang, et al 1994). In fact, these LAMP-positive 
compartments rich in MHC class II molecules constitute major class II peptide-
loading compartments in APC. Co-localisation of Leishmania with MHC class II 
molecules within these compartments enables access to the host class II pathway. It 
is this cellular compartmentalisation which explains the association of Leishmania 
with host class II recognition in contrast to the class I recognition of other 
intracellular pathogens such as viruses. 
Until recently there was a long held assumption that the macrophage was the only 
cell which internalised Leishmania and was thus responsible for initiating and 
maintaining the host's cellular immune response. However, macrophages are 
inefficient at priming naive T cells. Resting macrophages do not express MHC class 
II molecules on their cell surface unless activated by IFN—y and other cytokines 
(reviewed by Overath and Aebischer 1999). Furthermore, escape mechanisms have 
been recently identified during the initial PM stage of the parasite which appear to 
subdue the macrophages' initial role in immune defence. Usually, following 
phagocytosis of pathogenic organisms, macrophages secrete a range of activating 
cytolcines such as IL-1, IL-12, TNF—a, acute phase stimulants such as IL-6, 
modulatory factors such as IL-10, haemopoetic stimulating factors such as M-CSF, 
GM-CSF and chemolcines. Interestingly, following experimental infection of bone 
marrow derived macrophages from susceptible and resistant mice with L.major 
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metacyclic PM in-vitro, there was minimal transcription of these factors, in 
particular, IL-12, MIP-1 a, TNF—a, IL-10 and iNOS (Reiner, et al 1994). The lack of 
early IL-12 induction following L.rnajor infection of mice was also observed in vivo. 
This contrasts with the readily inducible IL-12 and TNF—a observed in macrophages 
infected with other pathogenic organisms, such as Toxoplasma gondii, Listeria 
monocytogenes and mycobacteria (reviewed by Reiner, et al 1995). L.major AM on 
the other hand stimulate immediate macrophage transcription of IL-12 and TNF—a. 
(Green, et al 1990). Not only are PM relatively sheltered in their initial 
compartmentalisation within the macrophage but the host cell, unable to prime naive 
T cells, also cannot send the usual signals to activate the cellular arm of the immune 
response. It is due to these important observations that other cell types, such as DC 
with their unique property of priming naïve T cells, warrant further investigation. 
1.4.3 T helper cell differentiation into Thl and Th2 subsets 
Central to the cell mediated immune response required for intracellular parasite 
eradication are the lymphocyte subset of CD4+ T helper (Th) cells. Initial studies 
with murine CD4+ T cell clones demonstrated the existence of two sub-populations 
of Th cells, termed type 1 (Thl) and type 2 (Th2) based on mutually exclusive 
patterns of cytokine secretion in response to stimulation with concanavalin A (conA) 
or with antigen. Thl subsets produce the cytokines IL-2, and TNF-13 which 
activate macrophages to kill intracellular parasites and effect DTH (Mosmann, et al 
1986). Th2 cells produce IL-4, IL-5, IL-6 and IL10 and provide B lymphocyte help, 
particularly in the generation of IgG1 and IgE (Snapper, et al 1988). 
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Shortly after the recognition of two distinct subsets of T helper cells, studies using 
genetically inbred mice infected with L. major demonstrated the existence of these 
subsets in vivo (Locksley, et al 1987; Scott 1991; Boom, et al 1990). BALB/c mice 
susceptible to progressive disease with L. major infection secrete IL-4 in draining 
lymph node cells whereas resistant mice, including C57/BL6, CH3 and CBA strains 
release IFN—y and lymphotoxin in regional lymph nodes. Thus the non-healing 
phenotype correlates with a Th2 response while Thl differentiation occurs in those 
mice able to contain infection and self-cure. Subsequently it was shown that the 
capacity of Leishmania-specific CD4+ T cells to passively transfer disease resistance 
or susceptibility to immune depleted naive mice correlated with the host production 
of Thl or Th2 cytokine patterns (reviewed by Reiner and Locksley 1995). 
Extensive research has focussed on the mechanism that mediates differentiation of 
these disparate Th subsets in mice of different genetic backgrounds. Initially, 
parasite antigens, particularly peptide epitopes from gp63, a conserved membrane 
protease immunogenic in most strains of mice, were investigated with the hope of 
finding a Thl -specific epitope that may serve as potential vaccine candidates 
(Jardim, et al 1990). Another potentially protective antigen, the LACK antigen 
(Leishmania homologue of receptor for activated C kinase) was identified and used 
in recombinant form in susceptibility studies as discussed below. Rather than show 
antigen driven T cell differentiation, these experiments in fact demonstrated that both 
Thl or Th2 responses could arise from the same antigen depending on the conditions 
during priming. Using limiting dilution techniques and transgenic mice, it has been 
established that naive T cells (Th0) have the capacity to differentiate into either Thl 
or Th2 types depending on the cytokine milieu at the time of priming (Fig 1.8). IL-4 
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plays an important role in mediating Th2 development and IL-12 in driving Th 1 
development from naïve precursors. It appears that the Th differentiation pathway is 
decided within the first few days (Leiby, et al 1993), if not hours (Launois, et al 
1995) of antigen/APC exposure. 
Subsequent work has highlighted the importance of the innate immune system in 
determining the role of T cell responses. Physical parasite containment correlated 
with T cell-independent production of IFN-y within the first 24 hours post infection 
in resistant mice (Laskay, et al 1995). NK cells were shown to be an important 
source of early IFN-y. Furthermore, IL-12 strongly enhanced NK cell activity. 
Important research has derived from the observation that the mouse phenotype could 
be altered by a range of immunological interventions. The susceptible BALB/c 
strain could be made resistant to infection with L.major and conversely resistant 
strains rendered susceptible by the addition of immunomodulating agents such as 
exogenous cytoldnes or cytolcine inhibitors. Importantly all interventions were only 
effective if given very early in the course of infection. These studies, outlined in 
more detail below, have further delineated the specific contribution of individual 
cytolcines. 
1.4.4 IL-4 
In the mouse phenotype susceptible to Leishmania, IL-4 excess appears to be more 
important in driving Th2 development than does the lack of IFN—y production. 
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Fig 1.8. Schematic representation of the Thl /Th2 paradigm. The APC presents an 
antigenic peptide (shaded diamond) to the naïve T cell (Th0) in the context of MHC 
class II peptide. Costimulatory molecules on the surface of the APC, B7-1 or B7-2 
and CD40, are required to activate the T cell. The balance of these costimulatory 
molecules and the predominant cytokine milieu, IL-12 or IL-4, directs the T cell 
differentiation pathway towards Thl or Th2 development respectively. 
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The severity of disease correlates better with the presence of IL-4 than the lack of 
• IFN—y production (Morris, et al 1993). IFN—y added to parasite inoculum 
significantly reduces the level of IL-4 production, but IFN—y treatment at inoculation 
and for up to six weeks could not reverse the progression of disease (Scott 1991). On 
the other hand anti-IL-4 antibodies administered to susceptible mice cured 
Leishmania infection (Sadick, et al 1990). Additionally 11-4 has a predominantly 
inhibitory effect on the parasiticidal function of macrophages (reviewed by Bogdan 
and Rollinghoff, 1996). 
So from where does early IL-4 arise? This question has provoked much controversy. 
In various experimental models several sources such as y6 T cells, eosinophils and 
cells of mast cell/basophil lineage have been proposed (reviewed by Launois, et al 
1997). Data from several sources point towards CD4+ T cells alone being sufficient 
for the production of IL-4 necessary for Th2 differentiation (reviewed by Reiner and 
Locksley, 1995). Of the potential CD4 + candidates, naive CD4+ cells were found to 
be capable of driving a Th2 response although the levels of IL-4 were very low and 
alone were not sufficient to account for this (Hsieh, et al 1993). Resting CD4+ 
memory cells produced significant IL-4 in response to challenge with antigen in vivo 
but minimally in vitro (Bradley, et al 1993). Furthermore this source would require 
the existence of a common environmental or cross-reactive self antigen. A subset of 
CD4+ T cells which express the NK1.1 antigen gained significant attention and was 
initially thought to provide the answer (Arase, et al 1992). These NK1.1+CD4 T 
cells are recent thymic emigrants which are MHC class I restricted and use a highly 
restricted repertoire of TCR. In vivo experiments with anti-CD3 rapidly invoked 
significant IL-4 responses in spleen although they comprised only 5% of the spleen 
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CD4+ population. As there is generally a lack of spleen cell stimulation in vitro it 
was suggested that these cells may be recruited to the spleen or lymph nodes 
following activation. However neither of these observations or speculation could be 
substantiated. The TCR on these NK1.1+ CD4+ cells have a Val4 chain paired with 
vp8, vp7 or V132 and accumulation of early IL-4 transcripts could not be 
demonstrated in the subset of CD4+T cells with these particular vp chains. 
Furthermore, NK1.1+ deficient mice still develop disease progression with a Th2 
response and an absolute requirement for MHC class II has already been shown 
(reviewed by Reiner and Locksley, 1995). 
Another CD4+ subset has been identified as the Most likely source of early IL-4. 
This subset of CD4+ T cells bears the heterodimer VI34Va8 receptor (Launois, et al 
1997). Expansion of CD4 cells bearing these receptors following infection revealed 
recognition by these cells of specific parasite antigen. This antigen was cloned and 
designated LACK (Leishmania homologue of receptor for activated C kinase). 
Subsequently, recombinant LACK antigen has been shown to induce IL-4 mRNA 
after 16 hours in the same restricted population of V134Va8 CD4+ T cells in BALB/c 
but not C57BL/6 mice. The specific epitope recognised by I—ad molecules was 
mapped to an 18-amino acid determinant of the LACK protein. VI34Va8 deficient 
BALB/c mice injected with the LACK antigen did not produce IL-4 and were able to 
control infection. Similarly, transgenic BALB/c mice rendered LACK tolerant by 
MHC Class II associated LACK expression in the thymus developed a Thl response 
and were resistant to infection with L. major (Julia, et al 1996). Thus it appears that 
the IL-4 required for 'Th2 development and susceptibility to L.major is produced by a 
restricted population of V134Va8 CD4+ T cells after cognate interaction with a single 
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antigen from the parasite. Whether the LACK antigen from Leishmania is solely 
responsible for the early IL-4 response or whether other antigens are recognised is 
unclear. The LACK antigen is unlikely to constitute a "Th2 epitope" as a small but 
detectable amount of IFN—y mRNA is expressed when resistant mice are stimulated 
with this antigen and immunisation with LACK and IL-12 can prevent the Th2 
response and protect BALB/c from subsequent infection. 
Just as the individual effects of certain cytokines were becoming established and 
researchers began using "knockout" mice with selective inactivation of 
immunomodulatory genes to further delineate their function, conflicting data were 
reported by two groups on the role of IL-4. Using IL-4 knockout mice (IL-4 4-) of 
BALB-c background, the susceptibility to Leishmania infection was reversed in one 
study (Kopf, et al 1996) but surprisingly unaffected in another very similar study 
(Noben-Trauth, et al 1996). These differences were puzzling but attributed in part to 
differences in the parasite strain used in these experiments. Subsequent work using 
IL-4Ra-deficient mice established that there probably are alternate IL-4 independent 
mechanisms for mediating a Th2 response and disease exacerbation. Another 
cytokine, IL-13 with similar properties to IL-4 which binds to the IL-4-Ra in 
addition to IL-13 receptors, was one such proposed mechanism (Noben-Trauth, et al 
1999). Interestingly, in these and other studies IFN-y production was unaltered in the 
IL-4 knockout mice and the level of IFN-y did not correlate with disease progression, 
indicating an absence of cross talk between Thl and Th2 cells in the L.major mouse 
model. Another hypothesis suggests that cell-intrinsic differences, specifically the 
ability of T cells to respond to the cytolcine milieu, particularly IL-12, may be 
significant (Guler, et al 1996). This is discussed further below. 
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1.4.5 IL-12 
Interleulcin-12 (IL-12) is produced largely by phagocytic cells but also by B 
lymphocytes and dendritic cells in response to bacterial or parasitic infection 
(reviewed by Trinchieri 1995). It is a 70 lcDa (p70) heterodimeric molecule 
comprising two covalently linked chains of 40 (p40) and 35 (p35) lcDa. The p35 
gene is constitutively expressed, usually at low levels, in most cell types whereas the 
p40 gene expression is restricted to cells producing IL-12p70. From the cells that 
produce the biologically active IL-12p70, free IL-12p40 is produced in excess of the 
IL-12p70 form in a ratio between 10:1 to 50:1. When human PBMC are stimulated 
with bacteria or bacterial products, IL-12 is produced up to levels of long/m1 of p40 
and ing/m1 of p70. IL-12 is similarly produced in mice, both in vivo and in vitro 
following stimulation of PMBC by bacteria, LPS and intracellular parasites 
(Gazzinelli, et al 1993). However recombinant IL-12p40 homodimers have been 
shown to inhibit the action of IL-12p70 (Mattner, et al 1993). It is important to 
consider these observations when reviewing IL-12 studies, where the original assays 
measured IL-12p40 rather than the more difficult to measure IL-12 p70. 
Other cell types producing IL-12 in the murine model have been identified. 
Keratinocytes are minor producers (Goodman, et al 1994) and mast cells, depending 
on their tissue location and exposure to different cytolcines, can be induced to 
produce IL-12 (Smith, et al 1994). Dendritic cells were then shown to produce IL-12 
(Macatonia, et al 1995) as discussed in detail below. 
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IL-12 appears to be an important bridging cytokine between innate and acquired 
immunity. In brief, IL-12 early in infection stimulates NK cells and T cells to 
produce IFN—y, which is important for activation and migration of phagocytic cells 
(Fig 1.8). IL-12 induces the production of other cytokines from these two cell types, 
TNF—a, GM-CSF, M-CSF, IL-3, IL-8 and IL-2. IFN—y induction, however, is 
probably its most physiologically relevant function. IL-12 is a growth factor for 
preactivated T and NK cells and enhances cytotoxicity of CD8 + T cells and NK cells. 
The production of IL-12 is regulated by other cytokines. It is enhanced by IFN—y 
and , GM-CSF and down-regulated by IL-4, IL-10 and TGF—p. In addition, TNF—a 
and IL-1 synergise with IL-12 to induce IFN—y production (reviewed by Trinchieri 
1995). 
Perhaps most important is the role of IL-12 in driving differentiation of CD4+ cells 
along the Thl pathway in response to antigen. Listeria monocytogenes-stimulated 
macrophages, a well studied model of bacterial infection, produce IL-12 and induce a 
Thl response which is completely blocked with neutralising anti-IL-12 antibodies 
(Hsieh, et al 1993). 
IL-12 plays a critical role in leishmaniasis. In the murine model of cutaneous 
leishmaniasis, IL-12 stimulates Thl cell differentiation and enhances NK cell 
cytotoxicity (Scharton-Kersten, et al 1995). Susceptibility to infection with 
Leishmania in BALB/c mice can be reversed if IL-12 is administered in vivo within 
the first week of infection. Conversely, anti-IL-12 treatment of resistant mice 
confers a susceptible phenotype. This induced susceptibility can be restored by 
simultaneous treatment with anti-IL-4 (Heinzel, et al 1995) demonstrating important 
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feedback mechanisms for cytokine control. In addition IL-12 can inhibit IL-4 
mRNA production even in the absence of IFN—y (Wang, et al 1994). 
Both resistant and susceptible strains of mice are able to mount an IL-12 response to 
infection with L.major PM in vivo. Similar levels of IL-12p40 could be detected by 
ELISA in the supernatants of the draining lymph nodes of both susceptible (BALB/c) 
and resistant (C3H ) strains of mice as early as 24 hours following footpad 
inoculation with L.major PM (Sypek, et al 1993). 
There is a suggestion that it is not an IL-4 effect but a lack of T cell responsiveness 
to IL-12 that confers susceptibility in BALB/c mice (Guler, et al 1996). In their in, 
vitro system BALB/c T cells became unresponsive to IL-12 within about a week as a 
result of some intrinsic property rather than the effect of any cytokine produced 
within the system. In particular, one mouse strain, BIO, appears be more sensitive to 
IFN—y up-regulation of the IL-12 receptor. 
The source of initial IL-12 production in Leishmania infection is unclear. As 
described above, macrophages only produce IL-12 when infected with the later AM 
stage of the parasite and not following PM infection. Recently, production of 
bioactive IL-12 by DC has been demonstrated and the role of IL-12 in mediating Thl 
development and IFN—y production has been recognised (Macatonia, et al 1995). 
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Table 1.2 Source and action of relevant cytokines (adapted from Locksley and Wilson 2000) 
Cytokine Principle cell source 	 Major biological effect 
IL-2 
IL-4 
IL-5 
IL-6 
IL-10 
IL-12 
IL-13 
IL-16 
IL-18 
IFN-y 
TNF-a 
TGF- 13 
GM-CSF 
M-CSF 
G-CSF 
T lymphocytes 
T cells, mast cells, basophils 
T cells, mast cells 
Many types; mononuclear phagocytes, T cells, 
endothelial cells 
Mononuclear phagocytes, CD4 + T cells, B cells, 
keratinocytes 
Mononuclear cells, B cells 
T lymphocytes 
Many types; T cells, B cells, eosinophils, epithelial 
cells, mast cells 
Macrophages, keratinocytes 
T cells, NK cells 
Mononuclear phagocytes, eosinophils 
T cells, NK cells, mast cells 
T cells, mononuclear phagocytes 
T cells, endothelial cells, monocuclear phagocytes, 
fibroblasts, mast cells 
Monocytes, endothelial cells, fibroblast 
Phagocytes, epithelial cells, fibroblasts 
T-cell proliferation, co-factor for B cell proliferation & Ig production 
Proliferation B & T cells; facilitates IgG1,IgE synthesis; inhibits macrophage activation; antagonises Thl 
Promotes antibody production, especially IgM, IgA, IgE, eosinophil expansion and activation; 
expansion T cell independent B cells 
Acute phase reactant; B cell proliferation & Ig production; T cell proliferation 
Inhibits cytokine synthesis by macrophages, T cells, NK cells; downregulates MHC class II on macrophages; 
antagonises Thl development; enhances B cell growth and antibody production; cofactor mast cell growth 
Induces IFN-y from T cells, NK cells; enhances T cell and NK cell cytotoxicity; growth factor 
for activated T cells; Thl development 
B cell proliferation and inununoglobulin production; enhances IgE and IgG isotype switching; 
downregulates expression of macrophage inflammatory cytokines 
Chemoattractant for T cells, monocytes, eosinophils, growth factor for CD4 + T cells 
Augment T cell production of IFN-y and TNF-a; related to IL-1 but uses different receptor 
Increase expression MHC I and II; activates macrophage cytocidal activity; Thl development; antagonises Th2 
Fever, enhances leucocyte endothelial interactions; cofactor for B-,nd T- cell proliferation; 
cytotoxic for some cell types 
Pleiotropic effects; generally and anti-inflammatory cytolcine 
Growth of granulocyte macrophage precursors; enhances macrophage and granulocyte function 
Growth of mononuclear phagocytes; enhances macrophage function 
Promotes granulocyte production; enhances granulocyte function 
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To date in vitro work with Leishmania has focussed on using AM and freshly isolated 
LC (Moll, 1995). As DC can produce IL-12, are situated in the dermis for initial host 
contact with L. major PM and play a pivotal role in establishing cell mediated 
immunity they became an obvious target for the investigation of host response to 
infection with L.major PM. 
1.4.6 Costimulatory molecule regulation 
The mixed lymphocyte reaction (MLR) is used to test for histocompatibility by 
measuring the T cell proliferative response to foreign or allogeneic .APC. CD4+ T 
cells account for most of the cytokine production and proliferation in the MLR and 
DC are by the far the most potent APC in a MLR (Steinman and Witmer 1978). With 
the aid of transgenic mice, DC have been shown to be 100 to 300 times more 
efficient than any other APC in inducing a primary antigen-specific T cell response 
to soluble antigens in vitro (Macatonia, et al 1995). This is particularly relevant in 
the context of L. major where macrophages were considered to be the only cells 
capable of internalising parasites and the predominant APC in the primary immune 
response. 
Antigen-loaded DC and antigen-specific T cells form aggregates that constitute a 
microenvirotunent optimal for the development of an immune response. An antigen-
specific T cell immune response is initiated as a result of interaction between a T cell 
receptor (TCR) and antigen expressed on the surface of an APC in the context of 
MHC (Fig 1.8). TCR ligation initiates signal transduction but is not on its own 
sufficient to initiate an immune response under most circumstances. An additional 
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signal provided by ligation of APC costimulatory molecules with T cell receptors is 
essential for clonal T cell expansion and cytolcine production. Without the second 
signal, ligation of the TCR alone can induce functional inactivation of T cells leading 
to a state of hyporesponsiveness or anergy (reviewed by Austyn 1998). 
1.4.6.1 B7-1 (CD80), B7-2 (CD86) 
The major costimulatory receptor on the surface of resting T cells is CD28 (Linsley 
and Ledbetter, 1993). CD28 has two distinct ligands on APC, B7-1 (CD80) and B7- 
2 (CD86). Both B7 molecules are members of the immunoglobulin gene superfamily 
and appear to be closely linked. In vivo, these two costimulatory ligands appear to 
differ in their ability to potentiate the differentiation of Th cells into Thl or Th2 cells 
(reviewed by Thompson 1995). In several murine models, disease has been 
modulated by blocking co-stimulatory molecule ligation with concomitant reversal of 
'Th cell phenotype. In the experimental 'murine model of allergic encephalomyelitis, 
simultaneous treatment with anti—B7-1 at the time of immunisation resulted in the 
generation of effector cells with a Th2 phenotype, abrogating disease. Treatment 
with anti—B7-2 resulted in the production of effector cells of a Thl phenotype, 
resulting in increased disease severity (Kucheroo, et al 1995). 
The B7 ligands also bind to CTLA4, a receptor on T cells closely related to CD28. 
In contrast to CD28, CTLA4 is not expressed on quiescent T cells but becomes 
detectable after TCR ligation and can be further augmented by CD28 costimulation. 
The role of CTLA4 in Th differentiation is not completely understood. Depending 
on circumstances, CTLA4 appears to be able to act as a costimulatory signal or as a 
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negative signal to down-regulate an immune response either by terminating a 
proliferative response or directly inducing apoptosis. CTLA4 binds B7-1 and B7-2 
with higher avidity than CD28. A recombinant form of CTLA4, CTLA4Ig, has been 
used as a competitive inhibitor of CD28 activation. In vivo, CTLA4Ig treatment can 
suppress the ability to mount T cell-dependent antibody production as well as 
suppress the ability to mount a cell-mediated immune response against tissue grafts 
(reviewed by Thompson 1995). 
The way in which B7 costimulatory molecules influence T cell differentiation is still 
unclear. It may be due to the timing of their expression in the immune response. B7- 
2 appears to be the predominant costimulatory molecule for activation of unprirned 
lymph node cells. In contrast B7-1 costimulation appears to be upregulated later 
during activation of an immune response and has been proposed to be the major 
costimulatory ligand present during persistent infections. B7-2 is rapidly induced 
and expressed at higher levels on dendritic cells compared to B7-1 (Inaba, et al 1994; 
Rattis, et al 1996). Furthermore, using antibody blocking experiments B7-2 was 
found to play a significantly greater role than B7-1 in the costimulatory function of 
dendritic cells. 
The regulation of B7 expression is also under cytoldne control. A range of cytokines 
have been explored with some conflicting findings, but consistently expression of 
both B7 ligands is induced by GM-CSF, IL-4 and down-regulated by IL-10. IFN-y 
also down-regulates B7-1. These modulatory effects are maximal within the first few 
days of culture (Kawamura and Fume 1995). The involvement of these 
38 
costimulatory molecules are therefore of particular interest in the investigation of the 
early DC dependent development of cell mediated immunity to Leishmania. 
1.4.6.2 CD 40-CD4OL 
CD40 and its ligand CD4OL (CD 154), both members of the TNF receptor 
superfamily, were initially thought to be exclusively involved in the regulation of 
humoral immunity. CD4O-CD4OL plays a critical role in isotype switching of B cell 
gammaglobulin synthesis and a defect in CD4OL causes the hyper-immunoglobulin 
M syndrome. CD40 is an integral membrane protein found on dendritic cells, B 
lymphocytes, follicular dendritic cells, macrophages and endothelial cells and 
interacts with CD4OL expressed on activated CD4+ T cells, some CD8+ T cells and 
basophils/mast cells (reviewed by Banchereau, et al 1994). Using CD40 and CD4OL 
deficient mice, researchers established that CD4OL is also required for protective 
cell-mediated immunity to Leishmania major and Leishmania amazonensis 
(Campbell, et al 1996; Soong, et al 1996). 
CD4O-CD4OL was found to be crucial for the synthesis of IL-12, NO and TNF—a by 
macrophages when challenged with L.major and L.amazonensis in-vivo. 
Furthermore, the CD40 ligation dependent IL-12 production by DC is also 
susceptible to downregulation by IL-4 and IL-10 (Koch, et al 1996). CD4OL is also 
the most potent stimulus in upregulating the expression of other costimulatory 
molecules ICAM-1, CD80 and CD86 on DC (Cella, et al 1996). Via its regulatory 
function on the expression of adhesion molecules on endothelial cells, CD4OL also 
effects the trafficking of effector T cells within the target organ (reviewed by NoeIle 
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1996). CD4O-CD4OL has a clear role in the priming of naive T cells via DC 
activation. The role of CD4O-CD4OL in the activation of the early immune response 
to L.major infection was investigated further in this work. 
1.5 Dendritic cells 
Dendritic cells are "professional" APC derived from bone marrow stem cells and 
distributed via the circulation to all tissues where they act as outposts of the immune 
system (reviewed by Knight and Stagg 1993). In the tissue they acquire and process 
antigen, then migrate by afferent lymph or blood stream to the paracortical T-
dependent area of lymphoid organs where they initiate T-cell responses (Fig 1.10). 
DC are a unique subset of APC. In addition to stimulating memory T cells, they are 
the only APC with the capacity to cluster and activate naive T helper cells. They are 
motile and have variable capacity for phagocytosis. Morphologically their name 
derives from the many elongated pseudopodial processes or dendrites which extend 
from the DC surface giving the cell a star like appearance (Fig 1.9). These dendritic 
veils provide an enormous cell surface area for antigen capture and presentation. The 
nucleus is generally horseshoe shaped and the cytoplasm has a paucity of organelles. 
They contain enzymes for degradation and processing of antigen, although little has 
been published in this area to date. 
Precursor DC (DCpre) derive from CD34+ bone marrow stem cells and circulate in 
the blood expressing MHC class II. They migrate to and become resident in non- 
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lymphoid tissues, such as epidermis (as LC) and other epithelia such as mucosa of 
the respiratory, urogenital and gastrointestinal tracts. They also become resident in 
the interstitial spaces of solid organs such as the heart and kidney but are absent in so 
called "immunologically privileged" sites, particularly the brain and testes. These 
resident DC are referred to as immature DC (DC) equipped with the capability to 
take up and process antigen. Epidermal LC are probably the best studied DCi mm and 
are identified by expression of CD 1 a and the presence of Birbeck granules 
(cytoplasmic structures formed by double membrane joinings which resemble 
racquets on electron microscopy). They also express other molecules of the CD1 
family, CD1c and CD1b which are important for antigen presentation (discussed 
below). Interstitial DCimm lack the Birbeck granules and most do not have CD1 
antigens (Bell, et al 1999). 
Other surface molecules on DC um„ enable homing and adhesion to particular tissue 
sites (reviewed by Bell, et al 1999). These include DCi mm expression of CD49d 13- 
integrin assisting passage through high endothelial venules into lymphoid organs, 
cutaneous lymphocyte antigen (CLA) interaction with E-selectin (CD62E) on 
activated endothelial cells in the skin and adhesion molecules ICAM-1, ICAM-2 and 
particularly E-cadherin on LC. The latter promotes adherence to surrounding 
keratinocytes which is down regulated when LC migrate out of the epidermis. CD44 
is a heterogeneous multifunctional molecule involved in DC trafficking (Weiss, et al 
1997). It is a receptor for the extracellular matrix component, hyaluronate, which is 
involved in lymphocyte homing and activation and is upregulated during migration 
of LC and DC to peripheral lymph nodes. Cytolcines, particularly IL-1 and TNF-a, 
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Fig 1.10. The life of a DC from progenitor to antigen capture and, presentation to 
lymphocytes. Precursor DC derived from CD34+ bone marrow stem cells circulate 
to peripheral tissue where they are situated for antigen capture. The immature DC 
loaded with antigen mature and migrate to lymphoid organs where they express 
antigen peptides on their MHC molecules to rare circulating antigen-specific 
lymphocytes. These reactive T cells become activated and further induce terminal 
DC maturation which in turn promotes lymphocyte expansion and differentiation. 
Activated T cells selectively traverse inflamed epithelium and migrate back to the 
injured tissue. Helper T cells secrete lymphokines and cytotoxic T cells eventually 
lyse infected cells. Activated B cells differentiate into B lymphoblasts after contact 
with T cell and DC and migrate to areas where they mature into plasma cells and 
produce antibodies to neutralise the pathogen. (Adapted from Bell , et al 1999). 
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have also been shown to mobilise LC and assist in migration probably via 
downregulation of E-cadherin (Cumberbatch, et al 1997). DC can both produce and 
respond to chemolcines, such as MIP- 1 a and mip-1p and RANTES (Sozzani, et al 
1995). DC imm express chemokine receptors CCR1 (receptor for RANTES), CCR5 
(receptor for MIP-la, MIP-10 and RANTES and CCR6 (receptor for MIP-3a) which 
are downregulated with maturation and appear to play an important role in migration 
(Fig 1.11). Additionally LPS from bacteria can stimulate many cell types to produce 
these and other chemokines and cytokines which can modulate DC movement and 
maturation (Reis e Sousa, et al 1999). 
The uptake of antigen may occur by one of several mechanisms. Macropinocytosis is 
a cytoskeleton-dependent type of fluid-phase endocytosis mediated by membrane 
ruffling and the formation of large vesicles (1-311m) which is constitutively expressed 
in DC (Sallusto, et al 1995). LC use the high affinity IgE receptors (FcERI) and most 
types of DC, use Fey receptors (CD32/FcyRII and CD64/FcyRI) for antigen 
capture. The mannose receptor involved in the internalisation of a variety of 
glycoproteins is expressed in high levels on DC. Unlike Fc receptors which are 
degraded with their antigen after internalisation, mannose receptors release their 
ligands at endosOmal pH and are recycled. This enables uptake and accumulation of 
many ligands by a small number of receptors and probably plays an important role in 
phagocytosis of microbes (Svensson, et al 1997; Reis e Sousa, et al 1999). DEC-205, 
another endocytic receptor is discussed in more detail below. Finally engulfment of 
apoptotic bodies by DCunra appears to be an efficient method of antigen capture for 
presentation, particularly in tumour and transplant immunology and in tolerance, 
which is beyond the scope of this review (Bell, et al 1999). 
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Fig 1.11. Schematic representation of surface molecule expression during DC 
maturation. When the DC precursors migrate into tissues to become resident DCi. 
they are primed specifically for antigen uptake. After antigen capture DCi rnn, undergo 
maturation during migration to secondary lymphoid organs, with increasing 
expression of surface MHC II, chemokine receptors, costimulatory molecules and 
cytokine secreting capacity. (Adapted from Bell, et al 1999). 
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After antigen exposure, DCt m,„ migrate via afferent lymph as "veiled DC" to the 
draining lymph nodes or other secondary lymphoid organs such as tonsils and the 
white pulp of spleen (Fig 1.10), where they localise to the T cell areas as mature 
interdigitating DC (Hart and McKenzie, 1988; Stagg and Knight 1993). During 
migration the maturing DC undergo major changes in their phenotype. The mature 
DC (DC,) can be distinguished by upregulation of expression of critical epitopes 
such as costimulatory molecules, CD40, CD80 and CD86, MHC II, adhesion 
molecules ICAM-1 (CD54), LFA-3 (CD58), CD1 la/c, actin-bundling protein p55 
(fascin) and chemolcine receptor CCR7 (Fig 1.11). Concomitantly the Fc receptor 
expression decreases along with most of the other chemokine receptors (Bell, et al 
1999). 
MHC class II loading of antigen is critical for activation of CD4+ T cells. In DCm. 
most of the intracellular class II MHC is found in late endocytic structures called 
MIICs (MHC class II compartments). As the DC mature they accumulate class II 
antigen in nonlysosomal vesicles (CIIV) and finally as DC mat peptide-class II MHC 
complexes are found on the plasma membrane for long periods of time, allowing the 
selection of rare antigen-specific T cells (Pierre, et al 1997). 
1.5.1 DC development 
The development of culture techniques using growth factors and cytoicines, in the 
1990s, enabled in vitro generation of large numbers of DC from haemopoetic origin. 
Subsequently it has been recognised that distinct developmental pathways give rise to 
several discrete subsets of DC (reviewed by Austyn 1998; Bell, et al 1999). They can 
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be divided into LC, myeloid DC, monocyte-derived DC and lymphoid DC. The first 
three appear to reside transiently in nonlymphoid tissues before migrating to 
secondary lymphoid tissues for the induction of immunity against foreign antigens. 
In contrast, lymphoid DC probably enter lymphoid tissues directly from the blood 
and play a role in the induction or maintenance of tolerance to self antigens. In this 
aspect, human DC have been the most studied. 
Myeloid DC and LC can be derived from CD34+ progenitors from cord blood or 
bone marrow by culture with TNF combined with either IL-3 or GM-CSF (Caux, et 
al, 1992). These cultured CD34+ develop along two independent pathways, defined 
by mutually exclusive expression of CD 1 a and CD 14 at an intermediate stage. Both 
populations eventually mature into DC but of 2 different types: CD1a+CD14- 
intermediates give rise to CD1a+CD14- LC (Birbeck granules, Lag, E-cadherin) 
while the CD1a-CD14+ cells become interstitial (dermal) DC which are CD1a ÷CD14- 
(lack Birbeck granules, Lag-, E-cadherin-, CD2+, CD9+, CD68+, Factor XI.! la). The 
two DC types are also characterised by specific activities (Caux, et al 1997). 
Interstitial DC have a potent and long lasting antigen uptake activity compared to LC 
which is mediated by mannose receptors. They are also uniquely able to induce 
naïve B cells to differentiate into IgM-secreting cells in response to CD40 ligation 
and IL-2. The addition of TGF-pl to similar cultures promotes LC development and 
inclusion of c-kit ligand (stem cell factor, SCF) increases yield (reviewed by Austyn 
JM 1998). DC can also be cultured from peripheral blood CD14+CD1a- mononuclear 
cells but differ from CD34+ derived DC in their requirement for GM-CSF combined 
with either IL-4 (monocyte suppressor) or IL-13. These DC are not terminally 
differentiated and resemble DCi. (Bell et al 1999). 
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In mice a similar situation occurs where bone marrow CD34 + progenitors can be 
driven along a DC differentiation pathway in the presence of GM-CSF. The addition 
of LPS or TNF-a induces further maturation. Flk-2/Flt-3 ligand increases the yield 
of DC in this culture system (reviewed by Austyn 1998). 
The fourth type of DC, lymphoid DC, have been described in both mice and humans. 
Altogether the evidence suggests that these bone marrow derived DC progenitors 
seed the thymus and generate DC which become involved in the induction of 
tolerance. Lymphoid DC progenitors also become parafollicular, interdigitating DC 
in the T cell-rich areas of secondary lymphoid tissues directly from the blood. In the 
latter, distinct subsets occur. CD8a -DEC205 -CD1 lb + DC can be isolated from the 
marginal zones of the white pulp of the spleen and CD8a=DEC205+CD11F DC from 
lymph nodes (Vremec and Shortman 1997; Steinman, et al 1997). The origin of these 
DC in unclear. They may originate from non-lymphoid tissues and enter through the . 
marginal zone of the spleen and the subcapsular space of lymph nodes ultimately 
homing to T-cell areas for cognate T cell interaction. An exciting possibility is that 
DC originating from different sites may induce different patterns of T cell cytokine 
production, specifically Thl from spleen DC and Th2 from Peyers patches (Everson, 
et al 1996). 
The pivotal role of DC is becoming increasingly apparent in many diseases and 
conditions. These range from autoimmune diseases to transplant and tumour 
immunology and infectious diseases. The former areas are reviewed elsewhere (Bell, 
et al 1999; Austyn 1998). The role of DC in leishmaniasis is further considered. 
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1.5.2 Role of DC in Leishmaniasis 
Leishmania is included in the growing list of intracellular pathogens, HIV, 
Influenzae, herpesviruses, Chlamydia, Listeria, Mycobacteria and Candida, in which 
DC have been found to be critical in regulating the host's immune response 
(reviewed by Bell et al 1999). Heidrun Moll's group first observed that murine 
epidermal LC were potent stimulators of antigen-specific T cell responses to L.major 
(Will,et al 1992). They then demonstrated that murine LC could take up whole 
L.major parasites in vitro (Blank, et at 1993). Internalised parasite numbers were 
small (average of two per cell) and uptake appeared to be via the complement 
receptor CR3 on LC. This observation underlined the purpose of LC as specialised 
APC rather than non-specific scavenging cells. These LC also appeared to harbour 
persistent parasites even after migration to regional lymph nodes where they 
stimulated antigen-specific T cell responses (Moll H, et at 1995). However, a 
recognised limitation of their study was the restricted capacity of the LC to 
internalise L.major only, in the AM form of the parasite. It is the PM form of the 
parasite which is transmitted by sandfly bite and will be encountered in the critical 
early stages of the host immune response. The interaction of PM with DC had not 
previously been examined prior to this thesis. 
As previously discussed, macrophages are paralysed by PM infection and not capable 
of producing IL-12. Recent evidence from in vivo experiments suggests that DC 
rather than macrophages may be the major source of IL-12 during the early stages of 
parasite infection (Reis E Sousa, et al 1997). The question therefore was whether DC 
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exposed to L. major PM were the source of IL-12 and whether they could activate 
naive T cells to initiate primary immune responses in vitro. 
1.5.3 CD1 presentation of non-peptide antigen 
DC express CD1 molecules. These comprise a more recently described important 
family of non-MHC antigen presenting molecules. The CD1 antigens are 
nonpolymorphic cell surface polypeptides, non-covalently associated with f32- 
microglobulin and bear some structural similarity to MHC molecules. They play an 
• important role in presenting nonpeptide, lipid-containing microbial antigens to T 
cells (Porcelli, et al 1992). They have been shown to be involved in host immune 
responses to Mycobacterium tuberculosis and Mleprae. DC bearing CD1 at sites of 
M. leprae infection portend a better prognosis (Sieling, et al 1999). Downregulation 
of CD1 + on DC infected with M tuberculosis while maintaining MHC molecule 
expression has been suggested as a mechanism of an evolutionary evasive adaptive 
response by the pathogen (Stenger, et al 1998). 
CD1 molecules have the potential to play an important role in the early immune 
response to L.major infection, particularly as several of the immunogenic epitopes, 
such as LPG are nonpeptides and could be presented by DC to T cells in the context 
of CD 1. This area had not been previously investigated and preliminary work was 
undertaken to further purify nonpeptide antigen from Leishmania cultures and 
discussed in more detail below. 
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1.5.4 DC surface membrane receptor 
The role of the mannose-fucose receptor in macrophage uptake of Leishmania PM is 
well established (Mosser, et al 1987). As described above, recent evidence suggests 
that marmose receptors on the cell surface are important in acquisition of antigen by 
DC. Specifically, DEC-205, an integral membrane protein homologous to the 
macrophage mannose receptor was found to be expressed at high levels on murine 
DC and was associated with antigen presentation (Jiang, et al 1995). DEC-205 binds 
carbohydrates and mediates rapid endocytosis by internalising coated pits and 
vesicles and is delivered to a multivesicular endosomal compartment that resembles 
the MHC class II-containing vesicles. Furthermore, antigens targeted to these 
receptors are presented by MHC class 11 100-10 000 fold more efficiently than 
untargeted proteins (Tan MC, et al 1997). DEC-205 is found on the lymphoid subset 
of DC as outlined above. The monoclonal antibody, NLDC-145, recognises this 
surface membrane protein and is used as a specific DC marker (Kraal, et al 1986). 
The possibility of involvement of this DEC-205 as a DC receptor involved in the 
uptake and processing of Leishmania was investigated. 
1.6 Vaccine development 
Immunisation against cutaneous leishmaniasis has been practised traditionally in 
Middle Eastern countries for a long time. Mothers expose their babies' buttocks to 
sandfly bites to prevent infection occurring on exposed body parts later in childhood, 
where disfiguring scarring may lead to social discrimination, particulaly in women. 
This practice and the innoculation of live PM in Israel and former Soviet Union has 
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been effective in preventing naturally acquired disease but is hampered by parasite 
persistence, delayed healing of resulting lesions and complications with secondary 
bacterial infection. Clinical trials of killed parasite have had only limited success. A 
killed Leishmania PM vaccine without adjuvant was used on troops in Brazil but 
gave limited protection (reviewed by Pearson, et al 2000). A large randomised study 
in Iranian schoolchildren comparing vaccination with clinical-grade preparation of 
autoclave-killed L.major (ALM) + BCG was only marginally more efficaceous than 
BCG alone (Sharifi I, et al 1998). The search for an effective, non-disease producing 
vaccine was aided by immunological advances in understanding the mechanisms of 
an effective primary immune response discussed above. 
The murine model of L.major infection has established that effective primary 
immunity to L.major infection results from the development of a Th 1 response 
characterised by the IL-12 dependent production of IFN-y from MHC class II-
restricted CD4+ T cells and from NK cells, as reviewed above. These observations 
form the basis of the current development of vaccines against leishmaniasis. Most 
vaccines used in humans induce neutralising antibodies to provide long term 
protection. For certain intracellular pathogens, including Leishmania, where cellular 
immune responses are necessary for protection, the development of suitable vaccines 
which are able to induce durable responses is hampered by the lack of understanding 
of the factors required for this. Effective vaccination against L. major in susceptible 
mice strains was achieved using recombinant IL-12 (rIL-12) with soluble leishmanial 
antigen (SLA) and subsequently with a recombinant leishmanial protein (LACK) 
(Afonso, et al 1994; Mougneau, et al 1995). Investigations have been extended to 
primate studies, but protective immunity was not long lasting. Adjuvants such as 
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alum (aluminium hydroxide gel) when used in addition to rIL-12 with heat-killed 
Leishmania amazonensis in rhesus macaques provided protective immunity to 
rechallenge at four weeks (Kenney, et al 1999). 
Advances have been made using DNA vaccination stategies which induce both MHC 
class I- and class II-restricted responses (reviewed by Gurunathan, et al 1998). The 
enhanced durability of DNA vaccines is probably attributible to CD8 ÷ T cell 
production of IFN-y. Vaccinating susceptible mice with plasmid DNA encoding the 
LACK antigen without additional adjuvant has been shown to confer protective 
immunity for over 12 weeks. Similar results were obtained using a clinical-grade 
preparation of ALM plus IL-12 DNA. Corresponding reduction in IL-4 producing 
T cells was also observed when the mice were rechallenged at 12 weeks. These 
vaccines also substantially reduced the parasite load in resistant strains of mice after 
infection. There appears to be a requirement for persistence of IL-12 for the continual 
induction of IFN-y production and to prevent apoptosis in Thl cells. Other 
researchers have confirmed that immunostimulatory DNA sequences (CpG-
containing oligodeoxynucleotides) co-inoculated with ALM drive the Thl effector 
response via IL-12 and IFN-y-dependent mechanisms (Walker, et al 1999). 
Potential candidates for a subunit vaccine include recombinant Leishmania proteins 
such as LeIF (Skeiky, et al 1995), synthetic immunogenic epitopes from the surface 
glycoprotein gp63 (PT3) and cysteine proteinases which elicit Thl responses in 
susceptible mice, and PSA (PM surface antigen-2) which also induce in vitro 
proliferative responses from peripheral blood mononuclear cells of human 
leishmaniasis patients (Kemp, et al 1998). Of particular interest is the possibility of 
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using DC to enhance the potency and longevity of a protective immune response to 
Leishmania infection. A single intravenous application of LC pulsed with L.major 
antigen in vitro provided protection in susceptible BALB/c mice against subsequent 
challenges with L.major parasites (Flohe, et al 1998). Genetic engineering of human 
DC to secrete functional IFNI and IL-12 as part of immunotherapy for leishmaniasis 
and other infections is another new and exciting area under investigaton at present 
(Ahuja, et al 1998). 
1.7 Specific Aims 
The aim of this thesis was to investigate whether DC play an influential role in naïve 
T cell differentiation and therefore host susceptibility and resistance in the murine 
model of leishmaniasis. Using an in vitro murine model of L.major infection, the 
following specific aims were the focus of this research: 
• To determine if DC internalised PM. 
• To determine if DC exposed PM were capable of initiating naïve T cell 
proliferation. 
• To determine if PM-exposed DC influenced naïve T cell cytolcine production. 
• To determine if PM-exposed DC produced IL-12 
• To examine if resistant and susceptible strains differed in any of the above. 
• To determine if specific DC endocytic receptor, DEC-205, was involved in 
L.major uptake. 
• To determine if a non-peptide excreted factor from L.major PM could be 
presented by DC to stimulate primary T cell responses. 
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An in vitro model was used to minimise as much as possible the complex 
intercellular communication which occurs in vivo so that the effect of isolated 
cytokines and specific intercellular reactions could be analysed under controlled 
conditions. To simulate as closely as possible the initiation of infection, the 
infectious PM stage of the parasite was used in cellular cultures with DC, . 
macrophages and T cells of nave mice of both susceptible and resistant phenotype. 
In vitro derivation of DC from stem cell cultures with cytokine enriched media, as 
discussed above was not considered ideal for this work. Although significantly 
greater quantities of DC would be available for experimentation using this method, 
these DC are already cytokine influenced by the inherent nature of their generation 
process and may not reflect the "naive" situation. On the other hand LC had already 
been used in murine studies and did not appear to be involved in uptake of the PM 
form of L.major. Immature DC were required and splenic DC were for technical 
purposes considered to be the most suitable. The different lineages of DC have been 
more clearly defined subsequent to this work. 
In summary, an in vitro murine model was developed tb observe DC interaction with 
the infectious PM stage of Leishmania and the subsequent influence of Leishmania-
exposed DC on the pattern of T cell development. Whether DC harbour the parasite 
or predominantly take up Leishmania for rapid processing and presentation of the 
parasite antigens to T cells was explored. The role of a recently characterised 
specific DC membrane protein as a potential candidate receptor for the uptake of 
Leishmania into DC was also investigated. Leishmania major PM cultures were set 
up in the laboratory and the optimum conditions determined for harvesting the most 
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infectious PM stage. Immature dendritic cells were isolated from spleens of young 
adult naive mice reared in pathogen free conditions using an established method of 
overnight adherence step and further purification. Firstly interaction of parasite with 
DC was assessed from parasite: DC co-cultures using light microscopy, fluorescence 
and electron microscopy and fluorescent activated cell sorting (PACS) analysis. The 
role of the DC receptor, DEC-205, by Leishmania was assessed with blocking 
antibody studies. DC production of IL-12 was assessed from the DC:Leishmania co-
cultures. Leishmania-exposed DC were then used in T cell proliferation assays to 
investigate primary T cell proliferation and T cell cytolcine production, particularly 
IFNI and IL-4. 
In Chapter 2 the methods and materials used in this research are outlined while the 
results are presented in Chapter 3. In Chapter 4 the results are discussed. A 
supplementary study funded by a WHO Director's Initiative Grant on which I was a 
co-applicant, to investigate a novel therapy for the treatment of cutaneous 
leishmaniasis refractory to routine therapy in Aleppo, Syria is described in Chapter 5. 
Finally, in Chapter 6, the findings and the implications that these results have for 
future research is discussed and final conclusions are drawn. 
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CHAPTER 2 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
2.1 Chemicals, reagents and media 
Most reagents, chemicals and media were provided ready for use in experiments. 
Where further preparation or modification occurred in the laboratory, details are 
outlined below. 
Complete medium 
Dutch modification of RPMI 1640 (Gibco, Paisley, UK) was supplemented with 
10% vol/vol fetal calf serum (FCS; Gibco, Grand Island, NY), 100 IU/ml 
penicillin, 100ug/m1 L-glutamine and 5 x 10 -5 M 2-Mercaptoethanol for culture of 
all mouse derived cells. For brevity it is referred to as complete medium (CM). 
Metrizamide 
Aliquots of 14.5g metrizamide (Nygaard, Oslo, Norway) were dissolved in 90mls 
Dutch modification of RPMI 1640 supplemented with 10% vol/vol FCS, 100 
IU/ml penicillin and 1004ml L-glutamine such that a concentration of 13.7% 
w/v metrizamide was achieved. The solution was passed through a 0.45= filter 
to exclude bacterial contamination. The metrizamide solution was then used in 
2m1 aliquots for centrifugation of spleen cells to isolate low density cells, as 
described below. 
Buffers 
FACS buffer was made by supplementing 500mls of sterile phosphate buffered saline 
(PBS) with 10mls of FCS (2%), 0.1g of sodium azide (0.02%) and 0.19g 
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EDTA(1mM), shaking to dissolve. It was kept refrigerated at 4 °C. Mini-Macs buffer 
was made by supplementing 500mIs of PBS with 5 mls EDTA and 0.5% bovine 
serum albumin. 
2.2 Leishmania Parasites 
Leishmania major is the species of Leishmania for which clear cut genetic 
predisposition to disease resistance and susceptibility has been best characterised and 
is therefore the species most frequently used in the experimental model of 
leishmaniasis. As this work seeks to answer questions central to disease outcomes 
and to remain consistent with the bulk of current research, L.major was selected for 
this model. 
Leishmania major strain JISH 118, originating in Saudi Arabia and passaged through 
BALB/c mice, was kindly provided by Dr Simon Croft, London School of Hygiene 
and Tropical Medicine. The PM were propagated in vitro at 25 °C  n Dutch 
modification of RPMI 1640 supplemented with 100 IU/m1 penicillin, 100 tig/m1 
streptomycin, 2mM glutamine and 10% vol/vol. During the first week of passage, 
the PM undergo an exponential log phase of growth and characteristically have 
slender, elongated forms. They reach stationary phase by day 5 -7 at a density of 
approximately 3.7x107/m1 (Fig 2.1). At this point the liquid culture medium is 
exhausted and acidification helps to induce transformation to infectious metacyclic 
PM (Sacks and Perkins 1984). The metacyclic PM are shorter and highly motile 
with a long but tightly coiled, extremely active flagellum protruding from a bulbous 
apex (Fig 2.2). They comprise up to 85-90% stationary phase PM. Due to the 
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Fig. 2.1 Growth curve of L.major PM in liquid culture medium at 25°C. 
Stationary phase is reached between day 4 and 7 when PM density reaches 
3x107/ml. 
Fig 2.2 Stationary phase metacyclic L.major PM (10-20 gm) in liquid culture at 
day 5 with characteristic morphology of extensively coiled, highly motile flagella 
protruding from bulbous apical end of an elongated body containing a round 
nucleus and rod-shaped kinetoplast. 
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high density of PM, for co-culture experiments PM were added directly from the 
stationary phase cultures in small microlitre volumes to the DCs, such that the 
PM:DC ratio was approximately 5:1, as described further below. 
To maintain a supply of parasites, PM from the 1st sub-passage were stored at -70 °C 
in 45% FCS and 10% dimethylsulphoxide (DMS0). When needed, aliquots were 
thawed for further passaging by rapid warming at 37 °C in Dutch modification of 
RPMI medium supplemented with glutamine, penicillin and streptomycin with 20% 
FCS and washed to remove residual DMSO. A maximum of five sub-passages were 
used for in vitro experiments to ensure optimal parasite integrity and infectivity. 
Leishmania are routinely cultured in parasite specific medium, such as 
Schneider's medium, which vary in composition to RPMI modified Dutch 
medium, a more general cell culture medium which was used for in vitro cell 
culture in this work. To ensure that using the latter had no detrimental effect on 
parasite development, the two culture mediums were compared measuring PM 
concentration at day 5, 7 and 12 of the first passage after receiving the parasites in 
Schneider's medium from the London School of Hygiene & Tropical Medicine 
(Table 2.1). 
Parasite-free culture supernatant was obtained from the stationary phase cultures 
by centrifugation through a 0.221.1m filter at 600g for 5min. 
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Day of passage Schneider's + 10% FCS 
(PM x 107/m1) 
Complete medium 
(PM x 107/m1) 
5 0.96 2.83 
7 2.4 3.6 
12 4.7 4.4 
Table 2.1 Comparison of two culture mediums, Schneider's and complete medium 
demonstrating that complete medium is as supportive as Schneider's medium for 
L.major PM development to stationary phase (3.7x10 7/m1) by day 7. 
62 
2.3 Animals 
Male C3H, C57/BL10 and BALB/c mice, 8 - 12 weeks old, were bred and reared 
in the specific pathogen free unit at Northwick Park Institute for Medical 
Research, Harrow, Great Britain. They were sacrificed by cervical dislocation. 
The C3H and C57/BL10 mice were the resistant phenotype and BALB/c, the 
strain susceptible to disease as described in chapter 1. 
2.4 Cell isolation 
2.4.1 Dendritic cells 
The number of DC circulating and resident in tissue are very small. To obtain 
sufficient cells for in vitro experimentation mouse spleen was used. 
DC were isolated and purified using a standard method in the laboratory. Single- 
cell suspensions Were prepared by pressing aseptically removed mouse spleen 
through a gauze cell strainer (40pm, Falcon) and washing in complete medium. 
The cell suspensions were incubated overnight in 25cm 2 Falcon tissue culture 
flasks at 37 °C, 5% CO2 at a concentration of approximately 4 x 10 6/ml. After 
incubation, non-adherent cells were aspirated from the cultures and gently layered 
over 2m1 of 13.7% w/v metrizamide (Nygaard, Oslo, Norway). Centrifugation at 
600g for 10 minutes separated the denser lymphocytes from the low density cells 
(LDC) which appear as a milky white interface at the top of the metrizamide 
layer. The LDC comprise about 80-90% DC (Knight SC, et al 1983). LDC 
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Fig 2.3 Isolation of DC and macrophages from mouse spleen 
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enriched for DC were aspirated from the interface, washed and counted (Fig 2.3). 
This method produced approximately 0.5 — 1 x 10 6 DC per spleen. 
With overnight incubation, the DC mature upregulating Class II and costimulatory 
molecules on their surface. For parasite uptake experiments, the period of 
incubation was varied to allow for collection of populations of DC of varying 
maturity. For mature DC, 17 - 24 hours incubation on plastic was required 
2.4.1.2 Further DC purification 
To enable positive selection of DC from LDC populations, a specific mouse DC 
antibody, NLDC-145 (Kraal GM, et al 1986) was kindly provided by Dr Kraal, 
Amsterdam. NLDC-145 was derived from supernatants of an NLDC-145 cell 
hybridoma line. The antibody was biotinylated using a biotinylation kit 
(Amersham, UK) with a biotin-streptavidin immunodetection system. 
Specifically, concentrated NLDC-145 supernatants were dialysed overnight into a 
sodium phosphate buffer with pH 7.2 using a slide-A-lyzer kit. Biotinylation 
reagent (biotinamide-caproic acid) was added to the supernatant at a ratio of 
approximately 50u1 per lmg of protein (as determined by UV absorbance at 
280mm) and incubated at room temperature for one hour with constant agitation. 
The sephadex column for separating biotinylated protein from unbound biotin was 
equilibrated with 25m1s of PBS containing 0.1% BSA. The lml NLDC 
supernatant sample was applied to the column and fractions of lml collected by 
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Fig 2.4 Biotinylation of NLDC-145. Nine 1 ml samples of NLDC-b in PBS were 
eluted from the sephadex column and protein content estimated using absorbance 
spectrophotometry. 
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elution with 9mls of PBS + 0.1% BSA solution. The 9 samples were tested for 
protein content using a spectrophotometer zeroed at wavelength of 280nm, the 
absorbance wavelength for IgG. Samples 2 to 5 had the highest protein content, 
as expected, and these were combined to proved the stock biotinylated NLDC-145 
(NLDC-b) for this research (Fig 2.4). Assuming the majority of the protein was 
IgG and using 1.4 as the extraction coefficient of IgG, the concentration of 
NLDC-b was calculated to be approximately 1.57 mg/ml or 10 nmoles/ml. 
The efficacy of the biotinylated NLDC was assessed. Positive labelling of the DC 
population was confirmed using 105 LDC per 20u1 volume exposed first to rabbit 
serum for 15 minutes, then biotinylated antibody or isotype for 20 minutes and 
washed twice. An avidin-FITC layer was applied for 20 minutes followed by 2 
washes and acquisition of data with the FACScan. A dose titration curve was 
obtained using 2u1, Sul and lOul aliquots of NLDC-b. Equal specific labelling 
occurred at Sul and 1 Oul aliquots (Fig 2.5) and Sul aliquots of NLDC-b were 
therefore used for further experiments. 
The NLDC-b was used in experiments which required further purification of DC 
from the LDC population. Highly purified DC were obtained by positive selection 
using immunomagnetic Mini-Macs columns (Miltenyi, Germany) and NLDC-b. 
To enable maximal availability of magnetic binding surface area on the column, 
non-viable cells from the non-adherent cell layer (which had a tendency to stick 
to the column) were removed by centrifuging the sample over Lympholyte M 
gradient for 20 minutes at 2400 rpm. Cells from the interface were collected and 
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Fig 2.5 Efficacy of the NLDC-b was established and dose titration ascertained that 
51.11 was sufficient for optimal DC labelling. A. Dot plot showing the DC region 
(R1) which labelled positively for NLDC-b. B. Histogram of the level of labelling 
with increasing concentration of NLDC-b and isotype control. 
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layered over metrizamide to isolate the LDC fraction as described above. The 
LDC were then resuspended in Mini MACS buffer and incubated on ice initially 
with rabbit serum for 15 minutes to reduce non-specific binding. Biotinylated 
NLDC-145 was then added for 30 minutes at 40u1 per 500 000 cells. Following 
two washes, avidin-microbeads were added and the cells incubated at 4° C for 15 
minutes before two further washes. The cells were then passed through a Mini 
MACS column to which the iron containing miCrobeads with attached NLDC-b-
labelled DC adhered. Thus positively selected cells were washed from the column 
after removal of the column from the magnet. The NLDC+ve DC, comprising 
>95% of LDC, were then available for culture after resuspension in complete 
medium (Fig 2.6). 
There were potential limitations to using biotinylated NLDC-145 as the only 
method of purifying DC. Firstly, NLDC-145 labelling may occur in activated 
macrophage populations (Kaye 1987) and the aim was to ensure exclusion of 
macrophages from the cell population analysed. NLDC-145 appears to label 
splenic DC of lymphoid origin and therefore may exclude potentially important 
DC of non-lymphoid origin from analysis. CD1 1 c is another marker which may 
be used to identify DC. CD11c+ DC, mostly found within germinal centres, are 
relatively immature DC which quickly mature in vitro and are potent T cell 
stimulators (Grouard, et al 1996). Therefore in other experiments positive 
selection of DC with a mAb to CD1 1 c bound to microbeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany) was also performed for IL-12 studies. Purity was 
confirmed by FACS analysis following labelling with CD11c (clone HL3, 
PharMingen). 
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Fig 2.6 Further purification of splenic LDC using positive selection of DC from the 
LDC derived over a metrizamide gradient with biotinylated specific DC mAb (either 
NLDC-145 or CD1 lc+) and Mini-MACS column. DC comprised >95% of selected 
population. 
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2.4.2 Macrophages 
Macrophages were used as positive controls in experiments analysing DC uptake 
of parasites. Macrophages were obtained following overnight culture of splenic 
cell suspensions prepared as above. Adherent cells were collected by dissociation 
from the tissue culture flasks in complete medium after refrigeration at 4 oC for 15 
minutes. Viability was determined by trypan blue dye exclusion and functional 
integrity was confirmed by their ability to phagocytose zymosan particles soaked 
in nitro blue tetrazolium (NBT, Sigma) and to subsequently reduce the NBT to 
blue-black formazan. 
2.4.3 Lymph node cells 
To assess the effect of Leishmania -ex posed DC on autologous lymphocyte 
proliferation, lymph nodes were excised aseptically from the same mice that the 
spleens were taken. Single cell• suspensions were obtained by pressing axillary, 
inguinal and brachial lymph nodes through a gauze cell strainer (4011m, Falcon). 
LNCs were washed twice in 8mls of CM for 10 minutes at 2000rpm and the LN 
pellet resuspended in 0.5-1.0m1 CM prior to use. In later experiments, 
lymphocytes were further purified to• T lymphocytes, by extraction of B 
lymphocytes over nylon wool columns. Specifically, using a sterile technique, 
0.6g of boiled and dried nylon wool was teased out to increase the surface area 
and autoclaved. It was then placed in a test tube with a 3 way tap and stop cock 
turned off. The wool was then soaked with 10mls of CM and warmed to 37 °C. 
The LNC collected above were resuspended in 2mls of CM. The column of nylon 
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wool was compressed to 6-7 mls by opening the stopcock and draining excess 
CM. The LNC suspension was added dropwise to the column and an additional 
1 ml of CM added to cover the top of the column. The column was incubated at 
37°C for a further 45 minutes facilitating adhesion of B cells to the nylon wool. 
The non-adherent T cells were then displaced by adding 10mls of CM dropwise to 
the column and collecting the effluent below. The purified T cells were then 
washed and resuspended in lml of CM for lymphocyte proliferation assays. Flow 
cytometric analysis confirmed moderate depletion of CD 19 positive lymphocytes 
using this method (Fig 2.7). 2 
2.5 Quantification of DC infection 
The initial phase of the research explored the possibility of spleen derived DC 
internalising L.major pm. Light microscopy was employed in the first instance. 
DC were identified by their typical morphology. Specifically, they are large 
mononuclear cells with elongated processes, a horseshoe shaped nucleus and 
paucity of organelles. When uptake of parasites was observed using this 
technique, further confirmation of the identification of the cells as DC and 
quantification of internalised parasites was performed with uptake studies using 
fluorescence and electron microscopy. 
2Elimination of B cells removes the possibility of B cells acting as APC for the lymphocyte 
proliferation assays. Using this method, however, also increases the CD8:CD4 ratio to 
approximately 50:50 which must be borne in mind when analysing the cytolcine assays from the in 
vitro cultures. 
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Fig 2.7 Freshly isolated lymphocytes (A) were enriched for T cells (B) after 
passing over nylon wool columns as demonstrated by flow cytometry. A high 
level of Class II and CD3 is maintained while the level of CD 19, a B cell marker, 
has been reduced by the columns. The bold lines represent isotype controls. 
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Fig 2.8 Preparation of DC:PM co-cultures for light microscopy. PM are incubated 
with DC in a ratio of approximately 5:1. 
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2.5.1 Light microscopy 
DC containing intact intracellular parasites were quantified by light microscopy of 
DC:PM co-culture samples which had been prepared on microscope slides by 
cytocentrifugation at 600g for 5 mins, fixed with methanol and stained with 
Giemsa (Fig 2.8). DC were suspended at approximately 5x 10 6 cells/ml for use in 
all studies. For infection assays 12 aliquots of 100u1 of this cell suspension were 
incubated with stationary phase (90% metacyclic) L.major PM in a 1:5 ratio. The 
optimal incubation period for maximal infection rate was determined from a time 
course, sampling cell co-cultures at 2 hourly intervals up to 48 hours. 
2.5.2 Fluorescence studies 
Double labelling of DC which had taken up PM was visualised with fluorescence 
microscopy and analysed with flow cytometry on a FACScan (Becton-Dickinson, 
San Jose, CA) using CELLQUEST software (Becton-Dickinson). The PM and DC 
were labelled separately as described below. 
2.5.2.1 PM labelling 
(i) PKH2 
Initially a green fluorescent cell linker molecule, PKH2, which is incorporated 
into the membrane lipid bilayers of cells, labelled PM efficiently. However this 
labelling was not stable. Repeated vigorous washing of labelled PM did not 
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prevent PKH2 being subsequently shed into the media, presumably due to rapid 
PM cell membrane turnover. This was evidenced by incubating PKH2-labelled 
PM with unlabelled PM at 37°C. Within 60 minutes dye was taken up by 
unlabelled PM (data not shown). 
Intracellular fluorescent probe 
A relatively new series of fluorescent probes that are retained in living cells 
through several generations and not transferred among adjacent cells in a 
population were adapted for this research by labelling live PM to track their 
course and ultimate fate in the cell cultures. The PM were labelled with either a 
red (chloromethyl-tetramethyl rhodamine: CMTMR, Biosciences, Cambridge, 
UK) or green (chloromethyl fluorescein diacetate: CMFDA, Biosciences, 
Cambridge, UK) intracellular dye. These molecular dyes cross the cell membrane 
and combine with intracellular thiols to form cell-impermeant thioether adducts 
which fluoresce following cleavage by intracellular esterases. 
The concentration of dye for optimal in vitro labelling with maximal viability was 
initially ascertained by dose titration curves with flow cytometry and 
quantification of motile fluorescing PM with fluorescence microscopy. First, 
serial dilutions of CMTMR or CMFDA were made by diluting 1 ul of 10mM dye 
stock in varying volumes of Dutch modification of RPMI 1640 medium 
supplemented with 10% vol/vol FCS, 100 IU/ml penicillin and 100p.g/m1 L-
glutamine. Approximately 10 6 stationary phase PM were washed in serum free 
media then incubated with serial dilutions of dye for 20 minutes. They were then 
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Fig 2.9 Establishment of optimal CMFDA labelling of PM. A. Dot plot of PM 
culture where Region 3 (R3) comprises the majority of PM, being cells of small 
size and little granularity. B. Histogram confirming the highest level of CMFDA 
labelling in R3. C. Dose titration curves established that 2.01.1M CMFDA labelled 
live stationary phase PM most efficiently without loss of PM viability. 
77 
washed twice and resuspended in the supplemented RPMI Dutch media and 
incubated at room temperature for a further 30 minutes. Following two subsequent 
washes they were ready for use in experiments involving FACS and fluorescence 
microscopy. These experiments established that a concentration of 2.0uM 
CMFDA or CMTMR produced a high level of labelling without loss of parasite 
viability (Fig 2.9). 
To ensure no leakage of dye occurred during the period of the cell cultures, 
labelled PM and unlabelled PM were incubated together at 37°C, such that any 
leakage of dye from CMFDA-labelled PM would be detectable by flow cytometry 
as merging of both unlabelled and labelled curves. There was no dye extrusion 
into the media from labelled PM for at least 48 hours (Fig 2.10). 
Fluorescent labelled PM were incubated with DC and macrophages in a ratio of 
5:1 for variable periods of time from two to 48hours. The cells were then labelled 
with monoclonal antibodies for further identification and prepared for 
fluorescence microscopy and flow cytometry as described below. 
2.5.2.2 DC labelling 
Following incubation with PM, the DC and macrophages were identified by 
labelling with a specific DC monoclonal antibody, NLDC-145 or the specific 
macrophage marker, F4/80 respectively and indirect conjugation with FITC. The 
co-cultured DC and PM were washed in cold FACS buffer then divided into 
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Fig. 2.10 L.major PM labelled with 2.0uM CMFDA were incubated with 
unlabelled PM in a co-culture (dotted line) for 48 hours and level of fluorescent 
labelling documented by the histograms. Persistent complete separation of the 
curves and maintenance of a high level of fluorescence when compared to 
CMFDA labelled PM cultured alone indicate total retention of dye for at least 48 
hours. 
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100111 volumes at a concentration of 5x10 6 cells/ml. Rabbit serum (20%) was 
added for 20 minutes to reduce non-specific binding of the subsequent mAb. 
NLDC-145 5111 and F4/80 50p1 were added separately to DC and macrophage cell 
suspensions for 20 minutes. Rat IGg2a and rat IGg2b were the isotypes used for 
NLDC-145 and F4/80 respectively. After 2 washes in the cold centrifuge, 21.1,1 of 
the second layer anti-rat Ig-FITC (DAKO) was added for 20 minutes. Following 
two further washes, the cells were then fixed to microscope slides with methanol 
after cytocentrifugation for five minutes at 600g. 
2.5.2.3 Fluorescence microscopy 
Glycerol (10%) was added to the slides prepared above and a coverslip fixed so 
that the cells could be visualised under oil immersion with 100x objective on the 
inverted fluorescence microscope fitted with filter blocks for dual fluorescence 
(Zeiss Axioscop). Those cells labelling green with NLDC-FITC containing 
intracellular red (CMTMR) fluorescing parasites were recorded as Leishmania-
positive DC (Fig 2.11). Similarly, those cells labelling green with F4/80-FITC 
containing intracellular red (CMTMR) fluorescing PM were recorded as 
Leishmania-positive macrophages. The rate of Leishmania uptake was indicated 
by the number of parasites observed per cell. 
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2.5.2.4 Fluorescent Activated Cell Scan (FACS) 
Flow cytometry was performed on a FACS (Becton-Dickinson, San Jose, CA) 
machine and data analysed using CELLQUEST software (Becton-Dickinson). 
Dead cells were gated out on the basis of light scatter. DC were analysed by flow 
cytometry using a gate set on large agranular cells (Fig 2.12). CMTMR was used 
initially for fluorescence microscopy but the emission characteristics of the 
CMTMR probe precluded its use with flow cytometry. CMFDA alone was used 
for PM labelling for FACS analysis. The PM were labelled as described above. 
2.5.3 Electron microscopy 
Processing of samples for electron microscopy was performed by Mr Nicholas 
English in the APRG laboratory. To investigate DC internalisation of PM, DC 
and PM were incubated together in a ratio of 1 DC : 5 PM for varying periods of 
time from 4 to 48 hours. The optimal time period for analysis was identified at 24 
hours. 
The DC:PM co-cultures at 24 hours were pelleted and fixed in 3% gluteraldehyde 
(Agar Scientific, Cambridge, UK), pH 7.4 at room temperature for two hours. 
Cells were washed in phosphate buffer, placed in 1.5% low-melting point agarose 
and post-fixed in 1% osmium tetraoxide for 60 minutes at room temperature. The 
cells were washed overnight in distilled water. Block staining was then performed 
with 2% uranyl acetate in water for 4 hours in the dark, washed again and 
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dehydrated with graded acetone. The Samples were then infiltrated with Spurr 
resin overnight, then embedded and cured at 65 oC for 18 hours. The sections were 
stained with lead citrate and examined under a Jeol 100 CX transmission electron 
microscope (Tokyo, Japan) at 80 kV. 
DC and contaminating macrophages were identified on the basis of their 
characteristic morphology. DC were identified by their characteristic elongated 
indented nucleus, paucity of intracellular organelles and long dendritic veils. 
Macrophages lacked dendritic processes and had a heterogeneous cytoplasm with 
a variety of organelles and significant numbers of lipid vacuoles. DC containing 
parasites were quantified and categorised according to the number of parasites per 
cell, maturity of DC, and viability of the DC and parasite. Over 100 cells were 
counted and the experiment repeated 3 times. DC from both BALB/c and 
C57\BL10 mice were used to compare the rate of uptake and persistence of the 
parasite. Macrophages provided the positive control for parasite uptake and 
intracellular viability. 
In some preparations DC were further identified by immunogold labelling. 
Following 24 hour incubation with PM, the cells were washed in cold FACS 
buffer and divided into 100111 aliquots at a concentration of 5x10 6 cells/ml and 
labelled with either NLDC-145 2011.1 or the isotype IGg2a 20pil. After 30 minutes 
on ice, the cells were washed twice and the second layer goat anti-rat immunogold 
20nm applied at a dilution of 1:35. These were washed twice again after 30 
minutes. The labelled cells were then pelleted, fixed with 3% gluteraldehyde and 
underwent the same processing procedure and categorising as above. 
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2.6 Phenotypic analysis of DC 
To analyse the impact of L.major PM on DC, a battery of monoclonal antibodies 
(Table 2.2) were used to assess the DC surface molecule expression including 
MHC Class I and II, costimulatory molecules and adhesion molecules at various 
time points in 48 hour co-culture time course experiments. DC were resuspended 
in cold FACS buffer on ice. The cells were labelled for 15 minutes with pre-
determined optimal concentrations of fluorochrome-conjugated mAbs to detect 
specific cell surface antigens. 
All antibodies were purchased from PharMingen, San Diego, CA except for 
NLDC-145 (George Kraal, Free University, Amsterdam) and CD44 (Serotec Ltd., 
Oxford, GB). Isotype-matched control labelling was included in all experiments. 
As surface molecule expression on DCs alters with DC maturation, DC were 
exposed to L.major PM at various stages of maturity after removal from 
'overnight incubation' at time periods from 6 to 24 hours. 
To look more specifically at L.major PM infected DC, CMFDA labelled PM were 
co-cultured with DCs and analysis performed with flow cytometry to measure 
mean fluorescence intensity of the above fluorochrome labelled mAbs on 
CMFDA+ve DC. 
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Table 2.2 Phenotypic markers used to identify specific cell types 
Surface marker Clone Isotype 
I-Ak 	(C3H MHC class II) 11-5.2 Rat IgG2b 
I-Ad 	(Balb/c MHC class II) AMS-32.1 Rat IgG2b 
I-Ab,d 	• (C57/B10 MHC class II) 25'9-17 Rat IgG2b 
H-2Dd 	(Balb/C MHC class I) 34-2-12 Rat IgG2a 
H-2Dk 	(C3H MHC class I) 15-5-5 Rat IgG2a 
CD1 la 	(LFA-1) 2D7 Rat IgG2b 
CD1 lb 	(Mac-1) M1/70 Rat IgG2b 
CD54 	(ICAM-1) 3E2 Hamster Ig 
CDlie 	(integrin ax chain) HL3 Hamster Ig 
CD40 3/23 Rat IgG2a 
CD44 	(Pgp-1, Ly-24, H-CAM) IM7 
CD80 	(B7/BB1) 1G10 IgG2a 
CD86 	(B7-2) GL1 IgG2a 
CD40 	(ligand gp39) MR1 IgG2a 
DEC205 	(NLDC-145) IgG2a 
CD3 OKT3 Hamster IgG ' 
CD19 Rat IgG2a 
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2.7 Primary lymphocyte proliferation assays 
The function of DC after exposure to L.major was determined by their capacity to 
stimulate proliferation of syngeneic lymphocytes. Hanging drop cultures were 
used to measure antigen specific T cell responses as previously described (Knight 
SC 1987). 
In brief, enriched DC or macrophages were incubated with washed metacyclic 
L.major PM (cell to parasite ratio of 1:5) for 4 hours. Control DC and 
macrophages were incubated with medium alone. After washing, graded numbers 
(1000, 2000 and 4000/well) of these stimulator cells were cultured with varying 
numbers of lymph node cells (25 000, 50 000 and 100 000 LNC/well) in triplicate 
20 ul hanging drops in inverted Terasaki plates. The plates were inverted over 
saline and incubated for 3 days in a humidified atmosphere of 5% CO2 in air at 
37
o
C. They were then pulsed for 4 hours with lp,1 (equivalent to lpg/ml thymidine 
at a specific activity of 2 Ci/mmol) [3H] thymidine (Amersham International, UK) 
and harvested by blotting onto filter paper discs. The acid-insoluble material was 
counted using a liquid scintillation counter (Fig 2.13). This technique using low 
specific-activity thymidine in flooding conditions for a short pulse time results in 
low counts but these reflect the level of DNA synthesis Without the complication 
of limiting availability of thymidine or excessive radiation damage (Knight SC 
1987). Radioisotope incorporation was determined by liquid scintillation counting. 
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Fig 2.13 DC pulsed with PM for two hours were used in 3 day hanging drop 
cultures with syngeneic LNCs incorporating 3 H-thymidine after which they were 
harvested and lymphocyte proliferation measured by counts per minute (cpm) on a 
scintillation counter. 
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In later experiments, particularly where supernatant cytolcine analysis was 
performed, the lymphocytes were enriched for T cells by incubating LNC 
suspensions over sterilised nylon wool columns at 37 °C for 45 minutes to remove 
B cells as described above. 
Supematant was collected from stationary phase PM and passed through a 0.2uM 
filter. DC were pulsed with L.major culture supernatant (20% vol/vol) for 2 
hours, washed twice then co-cultured with syngeneic lymphocytes using the 
hanging drop technique detailed above. Similarly, lymphocyte proliferation was 
measured by incorporation of 3 [H] thymidine. 
2.8 Cytoldne Analysis 
2.8.1 IL-12 production by DC 
A two-site sandwich enzyme-linked immmunosorbent assay (ELISA) (BioSource 
International, Camarillo, USA) technique was used to detect the production of IL-
12p40 by DC stimulated with L.major PM. In a sandwich ELISA, the first 
antibody, which recognises the first epitope, binds to the bottom of a plastic well. 
The interaction of the cytokine with this antibody is demonstrated with a second 
antibody that binds on a different epitope on the cytokine. An enzymatic 
colorimetric assay was used to measure the reaction. The optical density was read 
with an ELISA-reader (Eurogenetics) and concentrations were calculated by 
means of a standard curve. 
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Fig 2.14 NLDC-145 or CD11 c selected DC were co-cultured for 40 hours with 
PM. The supernatant from the co-culture was analysed for IL-12p40 production 
using an ELISA technique. 
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It was imperative to ensure minimal macrophage and other IL-12-producing cell 
contamination for these sensitive assays. NLDC-145 or CD1 1 c selected DC from 
both strains of mice (approximately 5 x 10 6/m1) were incubated with PM at a ratio 
of 1:5 in 2001A1 complete medium for approximately 40 hours. Cultures were 
centrifuged through 0.22tim filters (Spin-X tubes, Costar, Cambridge, USA) for 5 
minutes and the supernatant assayed by ELISA (Fig 2.14). The lower limit of 
sensitivity for the IL-12p40 assay is defined by the manufacturers as the 
lowestconcentration of standard which shows absorbance greater than the mean 
absorbance of 0 pg/ml sample 4-2 standard deviations. It was calculated to be 7.8 
2.8.2 Supernatants from lymphocyte proliferation assays 
Supernatants from the cell cultures of the hanging drops were harvested on day 3 
of culture. In parallel with the lymphocyte proliferation assays described above, 
60 well Terasaki plates were used to collect supernatant from 30 x 20u1 wells of 
the following cell culture per 20u1 well: 10 5 syngeneic LNCs alone, 4000 DC co-
cultured with 105 syngeneic LNCs , and 4000 DC pulsed with PM co-cultured 
with 105 syngeneic LNCs. These "cytokine plates" produced samples of cell 
suspensions for "LNCs alone, LNCs + DC, LNCs + DC + PM and DC + PM". 
The cell suspension collected from 30 x 20u1 wells was centrifuged at 6500 rpm 
for 5 minutes. The supernatant was aspirated with fine-tipped pipettes and stored 
separately at -70°C for batch testing with ELISA kits as described below. The cell 
pellets were resuspended in Tr-reagent and frozen at -70°C for later mRNA 
analysis for IL-4, IFN—y and IL-12. 
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IFN—y and IL-4 were measured with the InterTestIm Mouse IFN—y and IL-4 
ELISA kits (Genzyme diagnostics, Cambridge, USA) according to the 
manufacturers instructions. Briefly, these were solid phase sandwich ELISA kits 
with 96 well microtitre strips coated with the cytokine specific antibody. Samples, 
including standards of known cytokine content, control specimens and unknown 
supernatants were pipetted into these wells in 1001.11 volumes in duplicate, 
followed by the addition of a biotinylated second antibody. During the first one 
hour incubation, cytokine antigen binds simultaneously to the immobilised 
(capture) antibody on one site and to the solution phase biotinylated antibody on a 
second site. After removal of excess second antibody, streptavidin-peroxidase 
was added and binds to biotinylated antibody to complete the four-member 
sandwich. After a second one hour incubation followed by washing to remove all 
of the unbound enzyme, a substrate solution was added, initiating a permddase 
catalysed colour change that was subsequently stopped by acidification. The 
absorbance measured on an ELISA reader at 450 nm was proportional to the 
concentration of cytokine present in the standards or supernatant. A standard 
curve was constructed by plotting the concentrations of the cytokine standards 
against the respective absorbance. The curve was non-linear and four-parameter 
regression analysis provided the best fit to the data, as per manufacturers 
instructions. The concentration in the supernatants was then determined using the 
standard curve after background absorbance of control medium had been 
subtracted. According to the manufacturer, the detection limit for both assays was 
determined to be 5 pg/ml after statistical analysis of ELISA results. The mean 
absorbance obtained with 5 pg/ml mIL-4 was greater than two standard deviations 
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above the mean baseline absorbance obtained form replicate zero control wells 
(wells containing all assay components except mouse IL-4 or IFN-y). 
IL-12 was also measured in the supernatants using an ELISA kit to detect the 
production of IL-12p40 (BioSource International, Camarillo, USA) as described 
above. 
Using these assays on supernatants from the lymphocyte assays enabled analysis 
of the effect of PM-pulsed DC on T cell cytolcine production, particularly IL-12, 
IL-4 and IFN-y, in both susceptible and resistant strains of mice. 
2.9 Cytokine blocking assays (anti-IL-12) 
To determine if T cell proliferation was driven by DC derived IL-12, further 
analyses were performed using anti-IL-12 monoclonal antibody (clone C17.15; 
Genzyrne diagnostics, Cambridge, USA) to neutralise IL-12 in the lymphocyte 
proliferation assays. This mouse antibody recognises the p40 subunit of mouse 
IL-12 either as a monomer, a homodimer or as a part of the p70 heterodimer. A 
concentration of approximately 1.0 1.tg/m1 was recommended by the 
manufacturers to adequately neutralise the proliferative effect of 20pg/m1 of 
recombinant mouse IL-12. 
Lymphocyte proliferation assays were set up with L.major PM-pulsed-DC as 
described above. An additional identical set of Terasaki plates were set up in 
parallel to the standard plates and each well was pulsed with 2 ill of anti-IL-12 
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antibody. The effect on proliferation was measured with the thymidine 
incorporation method as outlined and compared to control samples. 
2.10 Non-peptide antigen presentation by DC 
2.10.1 L. major supernatant fractionation 
Using the in vitro model above, it was established that DC could stimulate 
primary T cell proliferation. This finding prompted the question of whether DC 
pulsed with non-peptide antigen from the supernatant were capable of producing a 
similar response. 
To obtain protein free supernatant, stationary phase supernatant was treated with 
pronase. Parasite-free culture supernatant was obtained, as described above, from 
the stationary phase cultures by centrifugation through a 0.22pm filter at 600g for 
5min. The supernatant was desalted by dialysis overnight in distilled water using a 
slide-A-lyzer kit with a 10 000 MW threshold. To digest the protein, 
approximately 10 pi of pronase (Sigma) was used for 1 mg of protein as 
recommended. The salt free supernatant dialysate had an estimated protein content 
of 20mg/m1 and 1 ml was therefore incubated with 2001,11 of pronase for 48 hours 
at 37°C. Pronase self digests such that any residual pronase would have been 
eliminated by 48 hours. 4 
4 There are some filamentous proteoglycans which are predominantly carbohydrate but do have a 
protein backbone of alanine, proline and serine, which are notoriously resistant to pro teases 
(reviewed in Jig 2000). Therefore to exclude residual protein in the pronase treated supernatants 
they would need to be analysed by HPLC. 
93 
2.10.2 Fractionated protein in lymphocyte proliferation assays 
To establish whether this protein depleted supernatant was immunogenic, DC 
were pulsed with 10m1 aliquots, and used in 3 day syngeneic lymphocyte 
proliferation assays, quantifying the level of thymidine incorporation on a 
scintillation counter as outlined above. The controls used were DC alone and DC 
pulsed with unfractionated stationary phase supernatant. 
2.11 NLDC-145 Blocking Experiments 
To investigate whether DEC-205 was a major pathway for the uptake of L.major 
PM by DC, the effect of blocking DEC-205 receptors with NLDC-145 antibody 
was studied. NLDC-145 antibody treated DC subsequently exposed to L.major 
PM were analysed by light microscopy to quantify internalised PM and determine 
if there was a reduction in the number of PM internalised compared to controls. 
Additionally NLDC-145 treated DC pulsed with L.major PM were used in 
lymphocyte proliferation assays to determine if there was any reduction in 
immunostimulatory capacity of thus treated DC. 
Specifically, BALB/c and C57/BL10 DC at a concentration of approximately 5 x 
105 in 100 volumes were pulsed with a range of 20 - 301.11 of NLDC-145 
antibody for 1 hour prior to the addition of stationary phase L.major PM in the 
standard ratio of 1 DC: 5 PM. The DC:PM co-cultures were then incubated 
together for 24 hours with sampling at 4 hourly intervals for light microscopic 
quantification. The samples were compared to control DC pulsed with 20 tl of 
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isotype control antibody IgG2a antibody. NLDC-145 antibody treated DC and 
isotype control antibody treated DC were pulsed with stationary phase L. major 
PM for 2 hours in the same ratio for 3 day lymphocyte proliferation assays using 
the method outlined above. 
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CHAPTER 3 
RESULTS 
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RESULTS 
3.1 DC internalise L.major PM 
3.1.1 Light microscopy 
DC were cultured for 48 hours with stationary phase L.major PM in a ratio of 
approximately 1 DC:5 PM. The Geimsa stained cytospin preparations of the co-
culture sampled at approximately 4 hour intervals were quantitatively analysed for 
Dc uptake of PM. Approximately 100 cells were analysed per sample and the data 
represents the average of 5 experiments. DC were identified by their morphological 
appearance. They had a relatively homogeneous cytoplasm with elongated, indented 
nuclei and several long dendritic processes extending from the cell (Fig 3.1). 
Promastigotes were counted as internalised in the cell if whole or part thereof was 
identified (Fig 3.1). Uptake of PM was observed as early as 2 hours after incubation. 
Maximal uptake occurred at approximately 24 hours as shown in the time course 
experiments (Fig 3.2). 
The percentage of DC observed to have internalised promastigotes as measured by 
light microscopy of Geimsa stained cytospin preparations of DC:PM co-cultures 
peaked at approximately 25%. Parasites numbered from one to three per cell. This 
contrasted strikingly with the appearance of the contaminating macrophages which 
were• larger, with 10-20 AM in multiple parasitophorous vacuoles and which 
generally had more vacuolated, coarse, heterogenous cytoplasm. Furthermore even 
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Fig 3.1 Geimsa stained cytospin preparation of DC:PM co-culture at 24 hours 
demonstrating a DC with characteristic features of elongated horseshoe nucleus, 
dendritic processes and 3 PMs in the process of being internalised. The adjacent cell 
is a macrophage (M) with a rounded nucleus containing >5 PMs. 
Rate of uptake of L.major PM by DC 
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Fig 3.2 Percentage of DC with internalised PM measured at 4 hourly intervals using 
Geimsa stained cytospin preparations of DC:PM co-cultures peaked at approximately 
25% at 24 hours. 
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with sampling co-cultures for 5 days, AM were never seen within DC. No 
difference was observed between strains of mice. 
Interestingly, in many of the slide preparations close apposition of macrophages to 
DC, the latter often wrapped around the macrophage, was frequently observed (Fig 
3.1). The research schedule did not allow for investigations to further explore this 
observation but cross-talk between these two cell types, would appear to be highly 
likely. 
3.1.2 Fluorescence studies 
To corroborate this novel finding of L.major PM internalisation by DC, particularly 
with respect to further confirmation of DC identity, fluorescence microscopy and 
flow cytometry were employed. Fluorescence microscopy was another modality 
used to visualise parasite internalisation, with additional labelling of cells by 
fluorescent tagged, specific mAbs to differentiate DC from macrophages. Using flow 
cytometry large numbers of cells could be more accurately assessed to determine 
how many cells internalised parasites. 
3.1.2.1 Fluorescence microscopy 
Co-cultures of DC labelled with NLDC-145-FITC (green) and PM labelled with 
CMTMR (red) were sampled at 48 hours for cytospin preparation. The cells were 
visualised with an inverted fluorescence microscope using red and 
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B. 
Fig 3.3 Fluorescence microscopy demonstrating a DC encircling a macrophage 
(M) at the superior pole in this view. A. The DC labelled positively with NLDC-
145 FITC appearing as diffuse irregularly shaped apple green capping over the 
macrophage which did not label with NLDC-145. B. The promastigote (PM) 
and amastigotes (AM) fluoresced red with CMTMR when viewed through the 
green filter. Thus they appeared yellow when the red filter was used (as seen in 
A). A singular PM was visible in the DC cytoplasm. As occurred in the light 
microscopy studies, no AM were seen within DC. By comparison, the 
macrophage is packed with >10-20 AM. 
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green filters (Zeiss Axiosxop). Whole parasites could be seen within DC. The DC 
labelled positively with NLDC-145 FITC and appeared as diffuse, irregularly 
shaped, apple green speckled cells either alone or occasionally in close apposition 
with a macrophage when viewed through the red filter. The PM and AM labelled 
with CMTMR could be seen fluorescing red when viewed through the green filter. 
When viewed through the red filter, PM and AM appeared yellow. Macrophages 
were identified by the large number of intracellular AM and lack of NLDC-145 
staining. 
Approximately 20% of NLDC-145+cells had evidence of L. major PM uptake 
typically numbering between one and three PM per cell. As has occurred in the 
light microscopy studies, no AM were seen within DC. By comparison, the 
contaminating macrophages frequently contained >10 AM (Fig 3.3). 
Macrophages did not consistently and reliably label with the macrophage specific 
monoclonal antibody F4/80. This may be explained by the observation in original 
work with the antibody, that the state of cell activation modulates the expression of 
the F4/80 molecule with antigen stimulated macrophages generally expressing low 
levels (Austyn and Gorden 1981). In this work macrophages were readily identified 
by the cell morphology and the large number of intracellular AM. 
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Fig 3.4 Flow cytometric evidence of internalisation of L.major PM by DC. Spleen 
DC were incubated with CMTDA-labelled PM for 20hrs, double labelled With 
NLDC-145-PE and analysed by flow cytometry using a gate set on large agranular 
cells. A. NLDC-145+ DC acquire fluorescent material (FL1) from CMFDA-
labelled PM. B. No staining of DC was observed with an isotype-matched inAb or 
following incubation with unlabelled PM. C. Co-culture of labelled and unlabelled 
PM for 20hrs confirmed absence of spontaneous leaching of dye from PM. ( 
	 ) unlabelled PM, ( 	bold ) CMFDA-labelled PM, ( 	) co-culture of 
labelled and unlabelled PM for 20hrs. 
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3.1.2.2 Flow cytometry 
Using flow cytometry, the proportion of DC containing fluorescent dye could be 
quantified from DC co-culture with CMFDA-labelled PM for 20 hours at 37 0C. 
Approximately 30 % of the total cell population and 80% of the NLDC-145 + cells 
were CMFDA positive (Fig 3.4A,B). Therefore, by this method approximately 
80% of DC had evidence of PM internalisation. 
This was a significantly higher percentage than was observed with light or 
fluorescence microscopy. To exclude the possibility of leakage of dye from labelled 
PM and non-specific uptake by DC, co-cultures of CMFDA-labelled PM and 
unlabelled PM were established in parallel with the cultures of DC and PM. By the 
end of the culture period there was no evidence of acquisition of dye by the 
unlabelled population confirming non-leakage of dye from the labelled PM in culture 
(Fig 3.4C). This finding supports the suggestion that DC acquire fluorescent material 
as a result of an interaction with the parasite rather than by uptake of dye released 
into the medium. 
The discrepancy between microscopy and flow cytometry findings may be due to 
rapid processing of PM by DC following internalisation of the parasite, releasing the 
fluorescent dye intracellularly resulting in a positively CMTMR staining DC without 
intact PM. This is supported by the absence of AM-containing DC and suggests a 
more hostile intracellular environment not permissive to parasite survival and 
replication. There were no differences noted between strains of mice. 
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3.1.3 Electron microscopy 
To clearly delineate the intracellular uptake of PM and characterise the process, 
specifically whether they were found in PV, and to determine more definitely if any 
AM forms were present, electron microscopy of DC:PM co-cultures was performed. 
Enriched BALB/c and C3H spleen DC of 24 hours maturation were incubated for 24 
hours with metacyclic L.major PM. The co-culture was then centrifuged and the cell 
pellet was fixed for electron microscopy. A small contaminating fraction of 
macrophages enabled direct comparison of DC handling of the parasite with 
macrophage processing under identical conditions. One hundred cells were counted 
in each sample and the DC and macrophages, identified morphologically and by 
presence or absence of specific NLDC-145 labelling, were enumerated and expressed 
as a percentage of the total cell count. The number and stage of parasites found 
within each cell type was documented. The data is representative of 3 experiments. 
Approximately 90% of the viable LDC were identified morphologically as DC. Of 
the contaminating cells, 8% were macrophages and 2% lymphoid blasts. Electron 
microscopy confirmed DC uptake of L.major PM (Figs3.5, 3.6, 3.7). Approximately 
30% of DC internalised PM (Fig 3.5). The average number of parasites seen per DC 
was 2.2 PM. Some of these were seen within phagosomes. Classic PV were not 
typically observed in DC. No AM forms of L.major were observed in cultures 
maintained for an additional 24 or 48 hours and examined by light microscopy. 
Many of these cells with DC morphology were NLDC-145 + by immunogold 
labelling, supporting their identification as DC (Fig 3.7). 
104 
1 0 	PM 
debris 
2 	3 	4 	5 to10 
80 
70 
60 
El DC 
1111 mac 
gn 50 
e 30 
20 
10 
Number of Parasites per cell 
Fig 3.5 Internalisation of L. major PM by DC and macrophages (mac). LDC were 
incubated with PM for 24hrs, fixed and analysed by electron microscopy. The 
number of internalised parasites was determined for DC and macrophages 
identified by morphological criteria. Data is representative of 3 experiments. 
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Fig 3.6 Electron micrographs illustrating uptake of L.major PM by DC. DC were 
incubated for 24 hours with metacyclic L.major PM. Bar = 1 um. A. DC with 
characteristic indented elongated nucleus (N) and dendritic processes (P) 
containing a single promastigote (PM) in a well circumscribed phagosome. The 
PM nucleus (n) and flagellum within flagellar pocket (fp) are demonstrated. 
Bar=lum. B. DC containing 3 PM and material suggestive of degraded PM (D). 
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Fig 3.7 Electron micrograph of immunogold staining  of PM-bearing DC with 
LDC-145. DC incubated with L.major PM for 24 hours labelled with rat inAb 
NLDC-145 and EM goat anti-rat IgG: 20nin gold (arrows). Bar =lum. 
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Fig 3.8 Electron micrograph illustrating uptake of L.major PM by a contaminating 
macrophage in a 48 hour co-culture of DC and metacyclic L.major PM. Bar = 
lurn. A macrophage bearing multiple parasites in the process of transforming into 
AM within a parasitophorous vacuole (PV) seen below the nucleus (N). 
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In contrast, macrophages contaminating the DC preparation contained a higher 
parasite load with an average of 8 parasites per cell (Fig 3.5, 3.8). Parasite 
transformation into AM forms in PV were observed within macrophages (Fig 3.8). 
These data suggest that L.major PM are internalised by both DC and macrophages 
and that their fate within these two populations is different. A similar rate and 
pattern of DC internalisation of L.major PM was observed in all strains of mice. 
3.1.4 DC surface molecule regulation 
DC upregulate certain costimulatory molecules, CD40, CD80, CD86, adhesion 
molecules ICAM-1 and MHC class I and II molecules with maturation. DC isolated 
on metrizamide gradients after overnight culture of spleen cells were shown to be a 
population of mature cells expressing high levels of MHC antigen, co-stimulatory 
and adhesion molecules. Incubation of these DC with L.major PM did not effect the 
cell surface expression of any of the following molecules as assessed by mAb 
labelling and flow cytometry: MHC class I and II, CD40, CD80, CD86, CD54, 
CD44, CD11a, CD11b, CD1 1 c or CD4OL (Fig 3.9, 3.10, 3.11). 
Five experiments assessing costimulatory, adhesion and MHC antigen expression 
were performed. To illustrate the impact of L.major PM exposure on DC surface 
molecule expression when DC are exposed at various stages of maturity, the results 
of selected experiments are demonstrated in Fig 3.9, 3.10, 3.11 below. Results for 
both susceptible and resistant strains of mice were similar. 
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Fig 3.9 Flow cytometric illustration of the effect of L.major PM exposure on DC 
expression of costimulatory molecules CD40, CD80, CD86 and MHC class II when 
very immature, 2 hour non-adherent spleen LDCs are co-cultured with PM for a 
further 15 hours. The shaded area represents unlabelled DC, dotted line represents 
isotype control and the bold line, mAb labelling. A. In the control group, after a total 
of 17 hours culture, there was strongly positive labelling of the DC with CD40, 
CD80, CD86 and MHC class H. B. The addition of PM to the DC did not alter the 
level of expression of any of these antigens when compared to controls. Similar 
results were obtained for both resistant and susceptible mice. 
• 110 
CD44 
0 
CO 
N 
0 
0
o 
0 
10 	10 	10•0 	0 
PE 
CD54 	 Class I 
C 
7 N 
0 
(.) 
0 	0 10 
10 	0 10 	0 
FITC 
RTC 
C') 
C 
7 N 
0 
t.) 
0 	0 	10 	10 	10 	0 	10 	10 	0 	0 
PE 
0 	10 10 	0 	10 
RTC F1TC 
Fig 3.10 Flow cytometric illustration of effect of L.major PM exposure on DC 
expression of CD44, CD54 (ICAM-1) and Class I when DC of 16 hour maturation 
were co-cultured with L.major PM for a further 24 hours. The shaded area represents 
unlabelled DC, dotted line represents isotype control and the bold line, mAb 
labelling. A. The control DC show a high level of labelling of CD44, CD54 and 
Class I which persists with prolonged culture. B. The DC exposed to L.major PM did 
not have altered level of expression of these antigens. No differences were observed 
between mouse strains. 
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Fig 3.11 Flow cytometric illustration of effect of L.major PM exposure on DC 
expression of CD1 la (LFA-1), CD1 lb (mac-1), and CD1 lc when DC of 16 hour 
maturation were co-cultured with L.major PM for a further 24 hours. The shaded area 
represents unlabelled DC, dotted line represents isotype control and the bold line, 
mAb labelling. A. In the control DC there is a high level of co-stimulatory molecule 
labelling which persists with prolonged culture. B. The DC exposed to L.major PM 
did not have altered level of expression of these antigens. No differences were 
observed between mouse strains. 
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Fig 3.12 Flow cytometric illustration of effect of L.major PM exposure on DC 
expression of NLDC-145 when very immature, 2 hour non-adherent spleen LDCs are 
co-cultured with PM for a further 15 hours. A. After a total of 17 hours maturation, 
there was positive labelling of the control DC with NLDC-145. B. DC exposure to 
PM did not alter the level of expression of NLDC-145. Similar results were obtained 
for both resistant (C3H) and susceptible (BALB/c) mice as shown here. 
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Not all DC internalised PM as demonstrated above. Further analysis of the level of 
expression of costimulatory, adhesion and MHC antigens by CMFDA+ve DC was 
performed. There was effectively no difference in the level of surface molecule 
expression by L. major PM-infected DC compared to the whole DC population in the 
L.major-exposed sample (data not shown). DC were able to upregulate their 
expression of co-stimulatory, adhesion and MHC molecules unaltered by the 
presence of L.major PM. 
Due to the potential involvement of DEC205 with DC uptake of PM, the impact of 
PM exposure on the level of DC expression of NLDC-145 was examined. As was 
observed with MHC antigen and costimulatory molecules, NLDC-145 expression by 
DC was not altered by exposure to metacyclic PM (Fig 3.12). 
3.2 DC produce IL-12p40 upon stimulation with L.major PM 
Initial experiments used highly purified NLDC-145 selected DC to assess whether 
exposure to metacyclic L.major PM stimulated DC to produce IL-12. NLDC-145 + 
DC produced a low level of background IL-12 following a further 40 hour culture 
period. Exposure to metacyclic L.major PM significantly upregulated IL-12 
production in both resistant and susceptible murine strains (Fig 3.13). 
These experiments were repeated with a different method of selection, using a mAb 
to CD1 1 c, to ensure that the NLDC-145 + DC were not the only DC subtype capable 
of producing IL-12 in response to L.major PM exposure. In addition, macrophages. 
were cultured simultaneously under identical conditions to determine if macrophages 
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Fig 3.13. L.major PM upregulated the production IL-12p40 by NLDC-145 selected 
DC from BALB/c and C3H mice. 
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infected by L.major PM were contributing to the IL-12p40 being detected in the 
supernatant (Fig 3.14). 
Highly purified CD1 1 c+ DC were stimulated to upregulate the production of IL- 
12p40 following culture with PM for 48-72hrs (Fig 3.14A). Neither CD11c - LDC 
which were depleted of DC (<2% CD11c+), nor adherent macrophages produced IL-
12p40 under similar conditions (Fig 3.14A). PM stimulated production of IL-12 by 
both BALB/c and C3H DC (Fig 3.14B). Low levels of IL-12p40 were also 
consistently detected in cultures of unstimulated DC and in most experiments these 
levels were greater in cultures of BALB/c DC than in cultures of C3H DC (Fig 3.13, 
3.14). 
3.3 Primary Immune Responses 
3.3.1 DC stimulate primary T cell responses to L.major PM. 
DC pulsed with L.major PM or with cell-free L.major culture filtrates were able to 
stimulate primary T cell responses (Fig 3.15). The data shown is representative of 
more than 10 experiments. Primary responses were not consistently higher in one 
mouse strain than the other. 
Despite taking up large numbers of PM, adherent macrophages failed to stimulate 
naive T cells confirming that this APC population is unlikely to play a role in 
stimulating primary immune responses (Fig 3.16). The viability of the macrophages 
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Fig 3.14 L.major PM upregulated the production of IL-12p40 by DC. A. CD11c+ DC 
(left panel), CD! 1c DC-depleted LDC (centre panel) and adherent 
macrophages (right panel) were isolated from BALB/c mice and cultured for 48 or 72 
hrs in medium alone (4) or with PM at a DC:PM ratio of 1:5 (o). B. CD11c+ DC 
were isolated from the spleens of BALB/c and C3H mice and cultured for 48hrs in 
medium alone ( 0 ) or with PM at a DC:PM ratio of 1:5 ( 0 shaded). All culture 
supernatants were filtered and assayed for IL-12p40 by ELISA. 
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Fig 3.15 DC pulsed with Lmajor PM stimulated proliferative responses in naive T 
cells obtained from both BALB/c and C3H mice. 2000 DC pulsed with L.major 
antigens were incubated, in hanging-drop cultures, with syngeneic LNC (12,500 - 
100, 000 per well) for 3 days and proliferation measured by 3H-Thymidine 
incorporation. (O....0) LNC alone, (•---•) LNC plus control DC, (A.---A) LNC 
plus DC pulsed with PM antigen, (E--111) DC pulsed with PM culture supernatant. 
(A) BALB/c mice (B) C3H mice. The graph represents data from more than 10 
separate experiments. 
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Fig 3.16 DC, but not macrophages pulsed with L. major PM stimulated primary T 
cell responses. 2000 adherent spleen macrophages (A) or splenic DC (B) were 
pulsed with L.major PM for 24 hours and incubated, in hanging-drop cultures, 
with syngeneic LNC (12,500 - 100, 000 per well) for 3 days and proliferation 
measured by 3H-Thymidine incorporation. (•- - -M) LNC alone, (• 	•) LNC 
plus stimulator cells cultured in medium alone, (A._____A) LNC plus PM-pulsed 
stimulator cells. The graph represents data from more than five separate 
experiments. 
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was confirmed by trypan blue exclusion as outlined in chapter 2. The data shown 
is representative of more than five experiments. 
3.3.2 Anti-1L-12 and primary T cell responses to L.major PM 
To investigate the role IL-12 played in T cell proliferation and activation in this in 
vitro system-, anti-IL-12 mAb was added to the hanging drop cultures. The presence 
of anti-IL-12 did not reduce T cell proliferative responses in either resistant or 
susceptible strains of mice (Fig 3.17). The effect of anti-IL-12 on the cytokine 
production of the T cells is discussed below. The data represents three experiments. 
3.3.3 NLDC-145 blockade and the primary T cell responses to L.major 
The impact of blocking DC receptors, DEC 205, with NLDC-145, on the uptake of 
L.major PM was investigated with light microscopic analysis. Despite varying doses 
of NLDC-145 mAb addition to the co-cultures of DC and PM, no reduction in the 
rate of internalisation was observed when compared with controls. The rate of 
uptake in the control group was approximately 25% at 24 hours with an average of 
two parasites per DC (Fig 3.2). 
Similarly, treatment of DC with NLDC-145 prior to L.major PM exposure and 
subsequent co-culture in lymphocyte proliferation assays did not impair the 
stimulatory capacity of L.major PM pulsed DC to stimulate a primary immune 
response in either resistant or susceptible strain of mouse (Fig 3.18). 
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Fig 3.17 The proliferative responses in naive T cells obtained from C3H mice was 
not affected by the presence of anti-IL-12. (A) 4000 DC pulsed with L.major PM 
were incubated in hanging-drop cultures with syngeneic LNC (12,500 - 100, 000 per 
well) either alone or (B) with the addition of anti-IL-12 to the culture for 3 days and 
proliferation measured by 3H-Thymidine incorporation. 	LNC alone, 
(•—•) LNC plus LDC, ( 	) LNC plus DC pulsed with PM antigen. The 
graph represents data from three separate experiments. 
121 
9000 - 
8000 - 
7000 - 
6000 - 
5000 - 
4000 - 
3000 - 
2000 - 
1000 - 
o — 	• 	
 
• 
 
12.5 	50 	100 
Fig 3.18 The proliferative responses in naive T cells obtained from BALB/c mice 
was not affected by the presence of NLDC-145 blocking. In 3 day hanging drop 
cultures 2000 DC pulsed with L.major PM were incubated with syngeneic LNC 
(12,500-. 100, 000 per well) with either prior NLDC-145 treatment of DC (• 
• ) or with isotype control DC treatment (A 	A) and proliferation measured 
by 3H-Thymidine incorporation. (II 	) LNC alone. 
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3.3.4 Pronase treated supernatant 
DC were shown to have the capacity to stimulate primary T cell proliferative 
responses to pronase treated supernatant from stationary phase L.major culture. As 
the supernatant was treated with pronase, the assumption was made that only non-
peptide antigen was present in the treated supernatant. No reduction in the degree of 
lymphocyte proliferation was observed when treated supernatant was applied to the 
cultures compared with control supernatant. This suggests that non-peptide antigen 
may be the major component of the supernatant. These results were repeated in two 
experiments. 
3.4 Secreted Cytoidnes in the Primary Immune Response 
Supernatants aspirated from three day hanging drop cultures where L.major PM 
exposed DC stimulated primary immune responses (Fig 3.15) were analysed by 
ELISA to quantify the level of IFN-y, IL-4 and IL-12 produced in the co-cultures. 
3.4.1 IFN—y 
IFN—y was produced in low levels by LNC co-cultured with syngeneic DC in both 
susceptible and resistant mice after three days in culture. The level of IFN-y 
production dramatically increased in the same culture when DC had been previously 
exposed to Lmajor PM (Fig 3.20). The greater increase in IFNI elaboration in the 
resistant strain, C3H, occurred consistently in three repeated experiments, but was 
apparent only as a trend, not reaching statistical significance. 
123 
2500— 
2000— 
a. E 
El- () 	1500— 
cu 
1000— 
E 
X 	500— 
0 
12.5 	50 	100 
Fig 3.19 The capacity for DC to stimulate primary T cell proliferation when pulsed 
with stationary phase L.major supernatant was not reduced when the supernatant had 
been treated with pronase for 48 hours. In 3 day hanging drop cultures 2000 DC 
from BALB/c mice were pulsed with either control L.major supernatant (• •) or 
pronase treated supernatant (A 	A) and incubated with syngeneic LNC (12,500 - 
100, 000 per well). Lymphocyte proliferation was measured by 3H-thymidine 
incorporation . 	LNC alone. These data were reproduced in several 
experiments. 
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Fig 3.20 IFN-y production was enhanced in 3 day lymphocyte proliferation assays in 
both BALB/c and C3H mice in the presence of L.major PM. In hanging drop 
cultures, LNC (12,500 - 100, 000 per well) were cultured alone, with 2000 DC or 
with 2000 L.major- pulsed DC. A low level of background IFNI production in the 
supernatants from LNC alone and LNC incubated with DC (LNC+DC) was 
dramatically increased with addition of PM to the culture (LNC+DC+PM). There 
was a trend for the resistant murine strain to produce higher levels of IFNI. 
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Furthermore, the IFN-y response to L.major PM pulsed DC in the primary immune 
response was shown to be partly IL-12 dependent. The level of IFN-y production 
was reduced but not completely inhibited by the addition of anti-IL-12 to the hanging 
drop assays (Fig 3.21). Interestingly, anti-IL-12 mAb suppressed the production of 
IFN-y in the three day cultures but had no impact on the lymphocyte proliferation 
observed in the same primary immune response (Fig 3.17). 
3.4.2 IL-4 
IL-4 was barely elevated in the supernatants of LNC alone, LNC plus DC and LNC 
plus DC pulsed with L.major PM in susceptible as well as resistant mice after three 
days in culture. None of the supernatants in repeated experiments had a mean 
absorbance above the level which corresponded with an IL-4 concentration of 
5pg/ml, the lower limit of detection in these assays, thus indicating negligible IL-4 
production in this in vitro model. 3 
3.4.3 IL-12 
Exposure of DC to L.major PM up-regulated the production of IL-12 p40 in the three 
day culture (Fig 3.21) corresponding with observed lymphocyte proliferation (Fig 
3.15) culture. Additionally there was a trend for greater IL-12 p40 production in the 
resistant strain, C3H, compared to BALB/c mice, but was not significant in two 
repeated experiments. 
3 Negligible IL-4 levels is notoriously difficult to detect in part because it is consumed as it is 
produced. Using anti-IL-4 receptor antibodies may sometimes alleviate this problem but were not 
used in our experiments. 
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Fig 3.21 The addition of anti-IL-12 mAb to three day lymphocyte proliferation 
assays reduced the level of IFN-y produced by LNC cultured with L.major PM 
exposed DC compared to controls. 
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Fig 3.22 IL-12p40 production is increased in 3 day lymphocyte proliferation assays 
in both BALB/c and C3H mice in the presence of L.major PM. In hanging drop 
cultures, LNC (12,500 - 100, 000 per well) were cultured alone, with 2000 DC or 
with 2000 L.major- pulsed DC. A low level of spontaneous production of IL-12p40 
in LNC alone and LNC+DC was increased when the DC had been exposed to 
L.major PM. There was a trend for C3H to produce a higher level of IL-12p40 
compared to BALB/c. These results were repeated in 2 experiments. 
128 
The same pattern of IL-12p40 production also corresponds with the rise in IFN-y 
levels in the same supernatants as outlined above (Fig 3.20). 
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CHAPTER 4 
DISCUSSION 
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DISCUSSION 
4.1 The In Vitro Murine Model 
A major component of this thesis was the establishment of an in vitro murine model 
which could be used to analyse the role of DC in the primary immune response to 
L.major PM. A murine model was chosen due to the existence of resistant and 
susceptible strains which could be used to investigate whether DC were involved in 
determinants of disease susceptibility or resistance. To elucidate the mechanism that 
leads to selective priming of Thl and Th2 cells, the factors that cause naive T cells to 
differentiate down a Thl or Th2 pathway needed to be determined. Due to the very 
low frequency of a given T-cell antigen specificity in naive experimental animals, 
there is an expectation that LNC from a naive animal will not respond to stimulation 
with antigen in vitro. This has caused most investigators to analyse immune 
responses in intact animals. As the priming of CD4 cells is likely to be multifactorial, 
defining all of these factors in vivo is difficult. Hence an in vitro model was 
established. 
Titus and colleagues also developed an in vitro model using susceptible BALB/c and 
resistant CBA mice (Soares, et al 1997; Shankar and Titus 1993). With their model, 
cytokine patterns were analysed in the supernatants of naive "spleen cells" stimulated 
with L.major PM in vitro for seven days. Using their in vitro model they were able to 
define different cytokine patterns corresponding with susceptibility and resistance, 
however, the APC population in their studies was not identified. Their work is 
discussed in more detail below. 
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An alternative method of investigating primary immune responses is to employ TCR 
transgenic mice which are genetically manipulated such that over 90% of their T 
cells recognise one epitope of a single model antigen. Transgenic mice have been 
used extensively in the study of immune responses to leishmaniasis (Kamijo, et al 
1993; Dalton, et al 1993; Noben-Trauth, et al 1996; Kopf, et al 1996). However this 
system has several limitations. L. major is a complex dividing host of antigens which 
profoundly effects APC function in itself, such as the inactivation of macrophages by 
the PM stage as described above. Model antigens do not have these effects on APCs 
and furthermore they are internalised in endosomes, whereas L.major reside in 
phagolysosomes. Cytokines often need to be added to these systems for Th 
commitment to occur (Macatonia, et al 1995). From the outset, these mice have been 
significantly immunologically altered by the nature of their singular TCR specificity 
which would have a probable but unquantifiable impact on other cells intimately 
involved with the primary immune response. 
Generating significant numbers of DC to perform in vitro studies has been addressed 
with derivation of DC from stem cells of mouse bone marrow with a combination of 
cytokines. However for our purposes, bone marrow derived DC have already been 
influenced by exposure to cytokines and are therefore a further step removed from 
the true naïve experimental situation. Furthermore, functionally distinct DC subsets 
can be generated in these cultures by subtle manipulation of cytokines (Caux, et al 
1997) which further complicates investigating APC function. 
Systems to analyse primary T cell responses in vitro may prove valuable in assessing 
the itnmunogenicity of parasite components for use in potential vaccines. This study 
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has shown that the murine model developed here is successful in producing reliable 
and reproducible results. Furthermore, this study demonstrated for the first time that 
DC of both susceptible and resistant strains of mice were able to internalise L.major 
PM, produce IL-12 in response and stimulate naïve T cell proliferation with cytokine 
responses favouring Th 1 development. There were some limitations to this model 
and they are described in the context of the discussion of results which follows. 
4.2 DC internalisation of Lmajor PM 
This investigation demonstrated for the first time that murine DC take up L. major 
PM. With electron microscopy, PM could be seen within the DC, some within 
phagosomes. A number of observations suggest that the fate of PM within DC is 
distinct from that within macrophages. DC internalised small number of PM which 
did not reside within classic PV and did not differentiate into AM. In contrast, under 
identical conditions, macrophages contained a large numbers of parasites, including 
AM, within vacuoles. In macrophages the PV have been characterised for several 
Leishmania species with identification of specific cathepsins, hydrolases and 
membrane proteins (Lang, et al 1994). The DC phagosomes in which PM were seen 
will require further characterisation. 
Experiments in which DC were incubated with fluorescence-labelled parasites 
indicated a higher frequency of uptake of PM than was suggested by the presence of 
intact PM within DC in electron microscopy experiments (80% vs 30%). This may 
reflect rapid degradation of PM within DC, an interpretation which is supported by 
the presence of PM-derived debris seen within DC (Fig 3.6). This would be in 
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keeping with the role of DC as professional APC, capable of rapid antigen uptake, 
processing and presentation to T cells upon reaching regional lymph nodes. 
Internalisation of PM by DC probably occurs via macropinocytosis or mannose-like 
receptor or as yet other unidentified receptor uptake. The protective mechanism of 
utilisation of CR1 and CR3 macrophage receptors for PM and AM uptake, which 
prevents triggering of a destructive respiratory burst, is unlikely to be operating in the 
DC studied here. Interestingly the small numbers of AM which persist intracellularly 
in LC for prolonged periods also appear to use CR3 for their uptake (Blank, et al 
1993). 
LC, the DC of the epidermis, have been reported to be parasitised by L.major AM 
(Moll, et al 1993) but not PM (Locksley, et al 1988). LC differ from DC in the 
dermis and other tissues, particularly with respect to some cell surface molecules, 
level of maturity and capacity for specific antigen uptake (Caux, et al 1997; 
Geissmann, et al 1998). Thus, spleen derived DC may represent a population more 
akin to dermal DC, explaining the difference in uptake compared to LC. The 
conventional view of DC maturation is that antigen processing is most efficient in 
immature cells, particularly those that reside in external tissues such as LC (Shuler 
and Steinman 1985; Romani, et al 1989; Kampgen, et al 1991). These cells are not 
effective in clustering with and activating T cells, but they become so with 
maturation when they concomitantly lose their ability to process antigen. However, 
the reality is probably not so clear cut. DC from the afferent lymph maintain the 
capacity to process antigens even after 'maturation' in culture (Liu and MacPherson 
1995). Other researchers have demonstrated that spleen derived DC, after 16 hours 
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maturation on plastic, are very efficient at antigen uptake and processing as well as 
antigen presentation (Coates, et al 1996). Our results also argue against the view that 
the capacity to process antigens is lost as DC mature and become efficient at 
clustering and stimulating T cells. 
Recently published work has reported DC internalisation of L.major PM in a human 
in vitro system (Marovich, et al 2000). They cite a high rate of internalisation of 
intact PM (from 38% at day 1 to 70% at 72 hours) by DC and claim doubling of 
intracellular parasite number from 3.3 to 6.2 organisms per cell by the third day. The 
organisms have the appearance of intracellular amastigotes in their published 
photomicrograph suggesting that DC support intracellular parasite survival and 
replication. This was not characterised or discussed further. Opsonisation of L.major 
PM with 5% normal human serum before infection of DC may have increased PM 
uptake in Marovich's studies. It has been recently recognised that L.major PM bind 
to components of human serum, particularly IgM to facilitate subsequent invasion of 
neutrophils and macrophages via complement receptor CR1. This process, however, 
does not seem to be present in animal models of disease (Dominguez and Torano 
1999). In the mouse model, opsonisation with 5% normal mouse serum has not 
influenced uptake of L.major PM in other work (von Stebut, et al 1998). 
The DC used in Marovich's work were derived from PBMC using recombinant IL-4 
and GM-CSF with a standardised protocol (Sallustro and Lanzavecchia 1994), and 
were thus distinctly different from spleen derived DC. DC are heterogeneous, even 
within the spleen (Vremec and Shortman 1997). Therefore different DC are likely to 
differ in their interaction with L.major. The myeloid-derived DC may represent a 
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more pure population of a particular subtype of DC capable of phagocytosis. In 
particular, their DC population probably comprised less mature DC than the splenic 
DC used in our system, as suggested by the lower expression of CD86 on the former, 
and therefore possess a greater capacity for antigen capture. Although CD le cells 
are excluded from the population of DC by negative selection, Marovich's DC may 
have possessed some macrophage-like characteristics. It is not clear why CD83, a 
specific human DC marker was not used to positively identify DC, particularly 
infected DC, in their work. 
Avid uptake by DC of another intracellular pathogen, Histoplasma capsulatum yeasts 
was recently described by Gildea and co-workers (Gildea, et al 2001). They found 
that DC rapidly killed the yeasts, unlike macrophages which support pathogen 
replication, similar to our observations with L.major. Furthermore they demonstrated 
uptake of the yeast via an alternative DC receptor, very late antigen-5 (VLA-5), even 
though the DC possessed CD 18, a known receptor used for the uptake of 
Histoplasma capsulatum by macrophages. The difference in receptor usage may 
account for the ability of DC to inhibit the intracellular growth of Histoplasma 
capsulatum, possibly by triggering a different intracellular signalling cascade. A 
similar situation is probably occurring in our study and, as discussed above, is an 
area yet to be explored with the uptake of L.major by DC. 
Our findings were contradicted by another study which showed DC to be incapable 
of taking up L.major PM (von Stebut, et al 1998). Again, a different murine model 
was used, where the source of DC was murine fetal skin-derived (FSDDC). 
Immature FSDDC were propagated in a GM-CSF and M-CSF supplemented media 
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for two weeks and DC aggregates isolated by centrifugation and dissociated by 
trypsin/EDTA. Surface antigen expression indicated a different subgroup of DC, 
which additionally had been heavily pre-treated with cytokines and may have lost as 
yet undefined surface membrane properties for the internalisation of some antigens, 
including L. major PM. 
Enough evidence now exists to refute earlier observations that dermal macrophages 
are the only site of initiation of Leishmania infection (Locksley, et al 1988). It would 
appear that DC derived from the spleen in this model were at an optimal stage for 
antigen uptake and presentation as supported by other workers (Coates, et al 1996). 
Given that the results generated from this study, as well as the results of more recent 
work of other researchers, confirms the capacity for DC to internalise L.major PM, 
the mechanisms of uptake and pathways utilised in PM processing now needs to be. 
further characterised. 
The close apposition of infected DC with macrophages strongly suggest 
intercellular cross-talk and possibly priming and activation of macrophages which 
could be further investigated by analysing the costimulatory, adhesion and MHC 
antigens of such macrophages. Cross-talk or cross-priming has been observed in 
other systems. DC loaded with apoptotic bodies derived from macrophages 
infected with influenza virus can stimulate the proliferation of influenza specific T 
cells and the generation of class I MHC-restricted influenza-specific CD8÷ 
cytotoxic lymphocyte reactions (Albert, et al 1998). In the aqueous humour 
outflow tract of the rat eye, DC and macrophages have been observed in intimate 
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association with mast cells, the interactions of which may play a role in anterior 
chamber immune dysfunction (Ioffreda, et al 1992). 
Evidence is mounting to suggest that mast cells and skin DC interact. Mast cell-
derived TNF—a has been shown in vitro to upregulate certain integrins on LC in 
human tissue (Ioffreda, et al 1993). Fractalkine, is a membrane-bound CX3C 
chemokine constitutively expressed on DC as well as skin endothelial cells. The 
fractalkine receptor, CX3CR1 recently identified on murine mast cells has been 
shown to effectively mediate chemotaxis without degranulation, suggesting a 
possible role for specific skin cells, including DC, in tissue-specific homing of mast 
cells (Papadopoulos, et al 2000). No work to date has investigated the role of mast 
cells in the pathogenesis of leishmaniasis, an area which may have great potential. 
This area will be pursued further by the author of this thesis in the research facility 
she is associated with in her current position where mast cell research expertise is 
established, using the principles involved in the in vitro model described here. 
4.3 DEC-205 
The role of DEC-205, a DC mannose-like receptor in the uptake of Lmajor PM was 
investigated. Blocking experiments using the mAb, NLDC-145, to block DEC-205, 
had no impact on the uptake of L.major PM or the capacity of L.major-exposed DC 
to stimulate lymphocyte proliferation. However, DEC-205 is rapidly regenerated 
back to the cell surface membrane (Jiang, et al 1995) so there is a possibility that 
while DEC-205 does not play a predominant role in the internalisation of antigen, it 
may still be a carrier to assist in PM uptake. Another possibility is that the epitope 
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for NLDC binding is distinct from the ligand binding site and therefore does not 
compete. These observations also enabled studies to continue using purification of 
DC by NLDC-145 selection without concern that DC interaction with L.major may 
be affected by NLDC-145 treatment of DC. 
4.4 Costimulatory molecule expression by L.major exposed DC 
The splenic DC used in this work maximally expressed costimulatory molecules, 
CD40, CD80 and CD86, adhesion molecules CD44, CD54 and MHC Class I and II 
antigens, which suggests they were a more mature population of DC. This level of 
surface molecule expression was shown to be unaffected by uptake of L.major 
antigen. Other workers have described conflicting results (Marovich, et al 2000). 
Their specific analysis of L.major PM infected cells, using LPG labelling of DC to 
indicate infection, found that HLA-DR, CD86 and to a much lesser extent, CD40 was 
upregulated on LPG-Fve DC compared to controls. Again, this is consistent with the 
starting DC population being less mature, therefore greater differences may arise 
from incubation of Lmajor PM with DC at an earlier stage of maturation. 
Nevertheless in both systems L.major PM exposure did not inhibit maximal 
costimulatory, adhesion and MHC molecule expression an important consideration 
for future therapeutic studies with DC. 
4.5 DC production of IL-12 
Following incubation with PM, spleen DC were observed to up-regulate the 
production of IL-12p40. 	The cytokine was unlikely to be derived from 
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contaminating macrophages since it was observed in highly purified DC preparations 
and macrophage-enriched spleen adherent cells did not produce IL-12p40. 
Furthermore, L.major PM have previously been reported to inhibit IL-12 production 
by macrophages (Carrera, et al 1996; Reiner, et al 1994). Recent in vivo experiments 
in models of Toxoplasma gondii (Reis E Sousa, et al 1997) and L.donovani (Gorak, 
et al 1998) infection suggest that DC but not macrophages are the predominant 
source of IL-12 under conditions in which macrophages are not pre-primed by 
exposure to inflammatory stimuli. In our experiments with L.major, IL-12 release 
appeared to be a direct effect of the parasite on DC and did not require the presence 
of other cell types. Early in infection, direct stimulation of IL-12 release may be 
more important than pathways dependent on CD40 ligand expressed on activated T 
cells (Macatonia, et al 1995; Cella, et al 1996). We observed production of IL-12p40 
in cultures of PM-stimulated DC from both BALB/c and C3H mice. Collectively - 
these data suggest that DC are the likely source of IL-12p40 which has been 
observed in lymph nodes of both resistant and susceptible mouse strains following 
infection with L.major (Scharton-Kersten, et al 1995). 
IL-12p70 needs to be measured in these assays and the tests to do this became 
available only as the study period was drawing to a close. Recently, Marovich and 
co-workers used a very sensitive intracellular cytokine assay to determine the level of 
IL-12p70 in DC and indeed found an upregulation of IL-12p70 occurring in L. major 
infected DC (Marovich, et al 2000). Interestingly they also described a requirement 
for CD40 ligation of the DC to stimulate IL-12p70 production. 
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There are at least two subpopulations of CD11c+ DC in the spleen (Vremec and 
Shortman 1997; Leenen, et al 1998) NLDC-145 + CD8+ interdigitating cells are 
localised primarily in the T cell areas of white pulp whereas DC in marginal zones 
are NLDC-145 - CD8cc". The observation that the NLDC-145+ DC subpopulation has 
been reported to be the predominant producer of IL-12 (Pulendran, et al 1997) 
supports our findings of upregulation of IL-12 by NLDC-145 + selected DC upon 
exposure to L. major PM. Which subgroup of the CD11c + DC were the predominant 
IL-12 producers was not determined. The NLDC-145+ CD1 1 c+ DC were only a 
minority and what proportion of the IL-12 was produced by this sub-fraction was not 
analysed. Whether IL-12 was also released by other DC subsets remains to be 
determined. Again, DC from both BALB/c and C3H were capable of upregulating 
IL-12 in response to L.major PM exposure. 
The enhanced IL-12 production in the lymphocyte proliferation assays with DC had 
been pulsed with L.major confirms the presence of this cytolcine in the primary T cell 
response to L.major. The trend for the resistant mouse strain to produce more IL-12 
than the susceptible mice was an intriguing observation but needs to be confirmed in 
repeated experiments and also with other resistant murine strains. 
4.6 Primary immune responses 
DC, but not macrophages, exposed to L.major PM or PM culture supernatant were 
able to stimulate proliferative responses in lymph node cells from naïve mice of both 
BALB/c and C3H strains. Titus and colleagues also described stimulation of naïve T 
cells by L.major antigens in their primary in vitro system (Soares, et al 1997). 
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However, the APC were not identified in the `splenocyte' population used for 
restimulation of T cell blasts. They also described a requirement for whole viable 
parasites which was not necessary in our studies with isolated DC. It remains to be 
determined whether the stimulatory material in supernatants is actively secreted by 
the parasite or is derived from the organisms dying in culture 
We found no difference in the way DC interact with L.major PM between resistant 
and susceptible strains of mice. Specifically, both susceptible and resistant strains 
were equally capable of internalising L.major antigen, producing IL-12 in response 
and stimulating T cell proliferation with IFN-y production. Thus DC have the 
potential to present L.major antigen and induce Th 1 development in the early stages 
of infection. 
It appears that other factors outside the DC-antigen-T cell interaction may determine 
the phenotypic pattern of resistance or susceptibility to leishmaniasis. T cell 
responsiveness, in particular the capacity for T cell upregulation of its IL-12 receptor, 
may be one mechanism which contributes to disease susceptibility or resistance 
(Guler, et al 1996). External factors in vivo may suppress DC function. Splenic DC 
has been observed two months post-infection with L.donovani in susceptible mice 
(Basu, et al 2000). Disease progression in these studies is associated with impaired 
DC production of IL-12 and reduced MHC class II antigen expression and ability to 
stimulate IFN-y production by Leishmania antigen-primed T cells. IL-10 which is 
produced in significant levels in L.donovani infection is capable of converting 
immature DC into tolerogenic APC and down-regulate HLA-DR (Steinbrink, et al 
1997). Prostaglandins which are produced in copious quantities by Leishmania can 
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also impair the ability of maturing DC to produce IL-12 and therefore promote Th2 
responses (Kalinslci, et al 1997). 
Thus in using this in vitro system it appears that DC have an inherent capacity to 
internalise antigen and potentially drive a Thl response. This system therefore 
remains a useful tool for the testing of antigens which may promote development of 
Thl responses and could therefore be used in vaccination and therapeutic research. 
External factors and how they influence DC function need to be further investigated 
to optimise the antigen presenting capacity of DC in vivo. 
4.7 IFN-y and IL-4 
IFN-y was present at low levels in the supernatants from the lymphocyte proliferation 
assays in both susceptible and resistant strains of mice. Stimulation with L. major 
PM-exposed DC triggered a dramatic increase in IFN-y production within the 
cultures, consistent with the proliferative T cell response observed. Furthermore the 
IFN-y production was partially inhibited by neutralising IL-12, indicating that IFN-y 
upregulation is at least a partially IL-12 dependent process. 
IL-4 on the other hand was barely detectable, an observation found in other primary 
in vitro assay systems (Soares, et al 1997). Whether this finding is a true reflection of 
the production of IL-4 or is due to rapid consumption of the cytolcine could be 
addressed by using anti-IL-4 receptor antibodies. Alternatively, there may be another 
source of IL-4 which has not yet been elucidated. Mast cells are potent producers of 
IL-4 and IL-5, bear MHC class II antigen and also reside in the dermis. Whether mast 
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cells play a role in the primary immune response to L.major is an intriguing question 
that warrants further investigation. Yet other cytokines which have been reported to 
play a role in the initial response to L.major infection, such as IL-10 and TGF-I3 in 
particular also warrant further investigation in this primary in vitro system. 
Recent work has described the effect of specific splenic DC subsets on the regulation 
of T cell cytolcine production (Kronin, et al 2000). Specifically, CD8a: DC induced a 
much higher production of IL-3, IFN-g, GM-CSF and IL-2 in primary CD8 T cells 
and of IL-2, IL-3 and IL-10 production in primary CD4 T cells compared with CD8 + 
splenic DC. Interestingly, even when exogenous IL-2 was added to the primary 
cultures the higher level of cytolcine production was maintained. Thus evidence that 
the general control of T cell cytokine production by splenic DC involves factors 
additional to those that govern activation and proliferation of T cells is now 
emerging. As with our study, these authors reiterate that many other factors which 
influence T cell cytokine production may be operating in vivo. However, the tight 
rosette-like clustering of DC and primary T cells which is required to initiate an 
immune response may be quite well reflected by a reductionist in vitro which only 
examines DC:T cell interactions. The results of further studies quantifying the T cell 
• subsets in the nylon wool purified T cells and looking specifically at DC:T cell 
interactionsin this model will be of great interest. 
4.8 Non-peptide antigen presentation 
Of particular interest was the observation that DC could stimulate T cell proliferation 
after exposure to L.major stationary phase supernatant. Lymphocyte proliferation 
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was unaffected by elimination of the peptide component from the supernatant, thus 
suggesting that non-peptide antigen from L.major could be presented by DC to T 
cells to induce a proliferative response. The non-MHC encoded CD1 family recently 
emerged as an antigen-presenting system that is entirely distinct from either MHC 
class I, class II or related class I-like and class II-like molecules (Beckman, et al 
1994). CD1 molecules, present on DC are capable of presenting non-protein 
antigens to T cells, unlike the MHC system which presents exclusively peptides. The 
role of CD1 molecules is yet to be fully elucidated. Evidence to date suggests they 
may have a specific immunological function which could play a pivotal role in 
inducing a Th2 response via ligation of a specific conserved subset of NK1.1 ± T cells 
which are early producers of IL-4 (Bradley, et al 1993). Thus either alone or at least 
in concert with MHC antigen presentation, CD1 molecules may play a significant 
role in stimulating primary immune responses and further characterisation of their 
role in this system would be of particular interest. 
The immunostimulatory antigen in the supernatant may be a component of LPG. 
Due to time restraints, further analysis of the treated supernatant, with high 
performance liquid chromatography to establish the nature of its constituents was not 
performed. It would also be of importance to ensure pronase treated supernatanat was 
indeed devoid of protein, as discussed earlier, some proteoglycans secreted into the 
supernatant are notoriously resistant to proteases (Ilg 2000). Fractionating the 
supernatant into various constituents and using this in vitro system to measure 
proliferative T cell responses to different fractions would be of interest and could 
follow on from these preliminary studies. 
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CHAPTER 5 
SUPPLEMENTARY CLINICAL STUDY 
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SUPPLEMENTARY CLINICAL STUDY 
5.1 Introduction 
There is a great need for the development of safe, practical and efficacious treatment 
for cutaneous leishmaniasis (CL) as this disease affects 1-1.5 million people world-
wide annually (Desjeux 1996). Treatment for CL became a World Health 
Organisation/Tropical Disease Research priority in the 1990's. During my laboratory 
based research into the role of DC in the pathogenesis of leishmaniasis, I had the 
opportunity to partake in a pilot study trialing a novel nitric oxide based cream for 
the treatment of CL in Syria, an area hyperendemic for CL. 
Based on previous experience with nitirc oxide (NO) and its cidal properties for 
pathogens (Duncan, et al 1995), Professor Nigel Benjamin, at St Bartholomew's, 
London theorised about the potential role of NO-releasing creams in the treatment of 
leishmaniasis. Vanessa Yardley and Simon Croft, at the London School of Hygiene 
and Tropical Medicine, performed in vitro assays with Leishmania infected 
macrophages and in vivo studies with L.major in mice testing the efficacy of a range 
of creams which would release nitric oxide locally. The author was not involved in 
these studies. The details of these laboratory based investigations are described in 
the publication (Davidson, et al 2000) attached in the appendix of this manuscript. 
The encouraging results from the dose ranging in vitro macrophage studies and the 
murine studies prompted the initiation of a pilot study by Dr Robert Davidson and 
the author in collaboration with Professor Hratch Balaban, Department of 
Dermatology, University of Aleppo, Syria to investigate the clinical efficacy, 
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tolerability and practicality of NO-releasing creams in the treatment of patients with 
CL. This work was supported by a Director's Initiative grant from the UNDP/World 
Bank/WHO Special Programme for Research and Training in Tropical Diseases. 
The author's role as a co-applicant on the grant was to assist in setting up the study at 
the University of Aleppo's Dermatology clinics with Dr Robert Davidson and 
Professor Hratch Balaban and to analyse the results. 
5.2 Background 
Standard treatment of CL is by local injection of pentavalent antimonials into the 
lesions, or for more severe forms, systemic pentavalent antimonial injections. Local 
lesional treatment is painful, may be protracted for weeks or months in recalcitrant 
lesions and is not always successful. Parenteral therapy has significant side effects 
(reviewed by Berman 1996). Macrophages infected with Leishmania rely on NO 
production to kill parasites as reviewed in Chapter 1. The mechanism of NO 
production is via 5 electron oxidation of L-arginine by the inducible enzyme nitric 
oxide synthase (iNOS). iNOS is inhibited by Leishmania both directly and by an 
inhibitory effect of cytolcines regulating iNOS production (Bogdan et al, 1996). iNOS 
deficient mice are unable to control the spread of Leishmania (Diefenbach, et al 
1999). 
An alternative pathway for NO production is non-enzymatical acidification of nitrite. 
This produces nitrous acid (HNO2) which has an acid dissociation constant of 3.2, so 
that in the presence of a low pH complete conversion will occur, with subsequent 
decomposition of nitrous acid to various oxides of nitrogen, including NO thus: 
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NO2- + H+ --> HNO2 
2HNO NO3 + H2O <-> NO + NO2 
3HNO2 2N0 + NO3 + H+ + H20 
It is not clear which reactive nitrogen intermediate is responsible for NO mediated 
microbial killing in mammalian cells. Indeed, different organisms may be susceptible 
to different reactive nitrogen species (reviewed by Fang 1997). Acidification of 
nitrite results in a complex mixture of nitrogen oxides as well as nitrous acid. 
Nitrous acid, dinitrogen trioxide and nitrogen dioxide are all effective nitrosating 
agents, that is, NO+ donors (Dykhuizen, et al 1996). In vitro, L. mexicana 
amastigotes are rapidly killed and structurally damaged by the addition of nitrite to 
their acidified (pH-5.5) culture medium (Reece, et al 1995). The toxicity of the 
solution correlated with the concentration of a reactive nitrogen intermediate, nitrous 
acid, and was cidal to Leishmania in concentrations of 0.1 to 10 mM. 
NO has the property of rapidly diffusing through tissues. When NO encounters 
superoxide or oxidised haemoglobin it is rapidly oxidised to nitrate, and becomes 
inert. Topical treatment for CL, in which the parasites are found in the dermis to a 
depth of .5 mm or more, is problematic because of the very limited penetration of 
drugs through the skin. As NO is so freely diffusible, we reasoned that it may be 
possible to apply an acidified nitrite cream over the lesions of CL, and thereby 
generate enough NO exogenously to kill Leishmania without causing damage to host 
tissues. NO kills Leishmania in vitro at concentrations much lower than that which 
kills tissue cells. NO has a very short half-life, so it is difficult to measure, and 
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nitrate is often measured as a surrogate for NO production. We could not do this in 
our experiments because nitrite was a constituent of our mixture. 
5.3 Materials and methods. 
5.3.1 Drugs and Formulation 
The constituents of the NO-producing cream were made up separately. Potassium 
nitrite (KNO2), salicylic acid (SAL), ascorbic acid (ASC) (all from Sigma) and 
potassium chloride (KC1) (Merck) were each added separately to an aqueous base. 
Due to the short half-life of NO, the nitrite cream and acid containing cream were 
mixed immediately prior to application. 
The manufacturing department of the pharmacy at Northwick Park Hospital made up 
150g quantities of constituent creams which were despatched by courier to the study 
centre in Aleppo, and stored at 4 °C until dispensed. 
5.3.2 Tolerability in volunteers 
Two of the investigators, including the author of this manuscript, applied various 
combinations of the creams to the flexor surface of the forearm in circles of 3cm 
diameter twice daily for 7 days. Erythema and tingling of the underlying skin was 
noted. The erythema faded within three minutes after removal of the cream, 
suggesting that NO-mediated vasodilatation rather than an inflammatory reaction had 
occurred. In short-term use, the creams were non-irritant. 
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5.3.3 Clinical study 
Dr Robert Davidson and the author of this thesis travelled to Aleppo with the study 
protocol and treatments to set up the pilot study in collaboration with Professor 
Hratch Balaban. After joint discussion, the trial protocol was established as follows. 
Adult patients with parasitologically-confirmed lesions of CL attending the 
Department of Dermatology, University of Aleppo, Syria, were eligible for 
enrolment. Patients gave informed consent, and the study was approved by the 
University ethics committee. Patients were excluded for the following reasons: 
pregnancy or lactation; any underlying condition which compromised the subject's 
ability to complete the protocol; underlying heart disease, renal failure, hypertension 
or any other medical condition requiring regular medication; steroid therapy, HIV 
infection, or any other cause of immunodeficiency. Lesions were considered 
unsuitable for NO cream treatment if they were on the face, or over a joint; were 
greater than 6 cm diameter; had obvious bacterial superinfection or were acutely 
inflamed or painful. 
At the start of treatment, the site and size of lesions were recorded, and the lesion 
photographed. The details were documented on recording sheet 1 (Fig 5.1, 5.2, 5.3). 
Trial cream was applied twice daily by the patient. Patients mixed similar amounts of 
the two constituents with a finger-tip on the lesion, to cover the lesion and about 0.5 
cm of skin on all sides of the lesion, once daily after washing and drying the lesion. 
Where anatomically possible, such as limb lesions, an occlusive dressing was placed 
over the lesion after applying NO cream. Where multiple lesions were present, all 
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Recording sheet 1: cutaneous leishmaniasis study 
Patient name 
date of birth / 	/19 	 M/F 
address 	 telephone number 
Cream to be used: 
Has patient read the information sheet? 	Y/N 
Has patient (or guardian) given written consent? 	Y/N 
Is patient able to attend for 8 weeks? 	 Y/N 
Is patient excluded from the study? Y/N 
Has parasitological confirmation been done 	Y/N 
Visit date measure 
lesions 
give 
cream 
adverse events 
(specify) 
sign 
day 0 
1 week 
2 weeks 
3 weeks 
4.weeks 
8 weeks 
At 8 weeks was the response to treatment 
Good 	= all lesions healed or substantially improved 
Fair = signs of improvement in some or all lesions, but none healed 
Poor 	= lesions worse or no better 
At 8 weeks was the patient's  use of treatment 
Compliant 	= used at least 5 times each week; collected all supplies 
poorly compliant 	= used erratically; missed 1 or more supplies 
incomplete 	= patient defaulted during treatment 
At 8 weeks was the tolerability of the cream 
Good 	= little or no local irritation; no systemic symptoms 
Fair = moderate local irritation ; any systemic symptoms (specify) 
Poor 	= could not continue use because of side effects (specify) 
Signed: 	 date: 
Fig 5.1 Record sheet 1 for entering patient data 
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Recording sheet 2: cutaneous leishmaniasis study 
Patient name 	 Cream used: 
Record site of all lesions as a dot 
Number 3 or less lesions which will be measured 
Indicate when each lesion was first noticed e.g. 
0 1(15/4/96). 
0 2 (30/4/96) 
Fig 5.2 Record sheet 2 for entering data on patient's lesions 
153 
Cream used: Patient name 
Measure each lesion: outline lesion 
and show area of ulcera ton 
Recording sheet 3: cutaneous leishmaniasis study 
day 0 
date 
PHOTO 
1 2 3 
1 week 
date 
1 2 3 
2 weeks 
date 
1 2 3 
3 weeks 
date 
1 2 3 
4.weeks 
date 
1 2 3 
8 weeks 
date 
PHOTO 
1 2 
Fig 5.3 Record sheet 3 for recording data on patient's lesion 
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were treated with NO cream. At weekly visits, a record was made of lesion size and 
adverse events, and cream for a further week was issued (Fig 5.1,5.2,5.3). After 8 
weeks of treatment, the response to treatment was graded as cured if all ulcers had re-
epithelialised and all nodules flattened, improved if signs of improvement in some or 
all lesions, but not all lesions, or unresponsive if lesions were worse or no better. 
5.4 Results 
Data was collected by Professor Hratch Balaban and his team as per data sheets (Fig 
5.12,5.2,5.3). This data was forwarded to our Department for collation and analysis. 
Forty patients with parasitologically-proven CL from Aleppo, Syria were treated with 
topical nitrite in aqueous cream combined with KC1, ASC, or SAL. There were 22 
males and 18 females. The median age was 30 years (range 5-80 years). There were a 
median of 2.2 lesions (range 1-9) on each patient. The lesions had been present for a 
median of 3.6 months (range 1-12 months). Several patients reported inflammatory 
or itching reactions to the creams, which was common with all preparations to some 
extent. There were no other adverse events. 
The response to treatment is summarised in Table 1. Only 11/40 patients (28%) 
showed improvement and only 5/40 (12%) were cured at 2 months. The maximum 
possible cure rate at 2 months, if all 6 patients lost to follow-up had been in fact 
cured, would be 11/40 (28%). The 5 patients who were cured had a similar number 
of lesions (median 2) as the 35 patients who were not cured and a similar duration of 
illness (median 4 months). 
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Treatment enrolled unresponsive improved cured Lost to 
follow up 
2%NO2/2% KC1 4 0 3 1 0 
2%NO2/2% salicylic acid 6 3 2 1 
5%NO2/2% salicylic acid 4 4 0 0 0 
2%NO2/2% ascorbic acid 18 8 5 2 3 
5%NO2/5% ascorbic acid 8 3 1 
11' 
1 
5 
3 	. 
Total 40 18 
Table 5.1 Clinical responses at 8 weeks of 40 Syrian patients with L. tropica 
cutaneous leishmaniasis, who were treated with NO-generating creams for 4 weeks. 
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A typical case is shown in the photographs (Fig 5.4A and B). A 34 year old lady had 
6 nodular lesions on her legs and one ulcerated oozing lesion on the lateral aspect of 
her right lower leg. The ulceration was 1.5 cm in diameter and had been oozing for 
nine months. The slit skin smear was positive for Leishmania. She was treated with 
5%NO2/5% ASC under occlusion. After 1 week, the ulceration and oozing persisted, 
and the nodular lesions were noted to have become inflamed. After two weeks of 
treatment the ulcer had become dry and the nodules less infiltrated. After three weeks 
of treatment some blisters were noted around the lesions and the treatment was 
stopped. Application of 5%NO2/5% ASC to the patient's hand produced a similar 
reaction at 48 hours, suggesting she had become sensitised to the cream. Treatment 
was not re-introduced. By eight weeks all the lesions had healed leaving 
hypetpigmented areas. 
5.5 Discussion 
The topical treatment of CL is limited by the fact that the infection is located 
throughout the dermis, as deep as the subcutaneous tissues, and the penetration of an 
anti-leislunanial compound into a lesion is likely to be minimal. NO is a molecule 
which could, conceivably, diffuse into the dermis, because of its small size and 
ability to diffuse through aqueous solutions and lipid membranes. We had hoped to 
devise a method of acidifying nitrite over the surface of a CL lesion, and that NO 
might diffuse through the lesion in sufficient concentration to kill Leishmania but 
leave host tissues intact. Whilst nitrite combinations were efficacious in vitro and 
showed some benefit in murine CL, our clinical study was disappointing in both the 
low cure rate and the high rate of local, albeit minor, reactions. 
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I 
A. 	 B. 
Fig 5.4. A 34 yr old Syrian woman with L. tropica cutaneous leishmaniasis. The 
photographs show 3 of her 6 lesions before (A) and 4 weeks after treatment with 
5%NO2 plus 5% ASC cream (B). 
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The only topical treatment which has worked in controlled trials in CL was 
aminosidine 15% in methylbenzethonium chloride applied twice daily for 10 - 30 
days. This was effective in Israel in L. major CL (El-On, et al 1992) but produced 
burning and pruritis in 25% of patients and vesicle formation in 15% of patients 
(Soto, et al 1995). Recently, success was reported using a cream containing the NO 
donor S-nitroso-N-acetylpenicillamine at a concentration of 200 mmol/L. When 
applied five times daily for 10 days in an uncontrolled study, all 16 patients with L. 
braziliensis CL in Ecuador were cured, with only mild local reactions to the cream 
(Lopez-Jaramillo, et al 1998). 
There are several possible explanations for the low success rate in our study. Firstly, 
the species of Leishmania which causes CL in Aleppo is L. tropica (Ashford, et al 
1993) and this may be harder to cure than other forms of CL. L. tropica is known to 
have a slow evolution of lesions and a slow rate of spontaneous healing, with lesions 
healing in 10-14 months or longer (Bryceson 1996). This sets it apart from L.major, 
L. braziliensis and L. mexicana and the murine studies were performed with L.major. 
Prior treatment did not exclude the patient from the trial and there was little clinical 
detail on prior treatment. This would need to be more clearly documented as there 
may have been a bias in this study towards selecting patients with recalcitrant 
lesions. More prolonged therapy may also be worth considering, although the local 
adverse reactions may limit this. 
Despite the results presented here, we consider the principle of treating CL with NO 
releasing creams remains important to continue to assess for efficacy. Other NO- 
donor compounds such as glyceryl trinitrate may have less local side effects and 
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should be considered. There are other regions where L.major is the predominant 
cause of CL and with NO releasing therapy could be trialed in those patients. There 
is enough demand for better CL therapy and encouraging evidence from several 
studies, including ours, to suggest that formal randomised, placebo-controlled trials 
with NO releasing treatment should be undertaken. 
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CONCLUSION AND FUTURE DIRECTIONS 
The murine in vitro study, which comprises the major part of the manuscript, and the 
clinical study have contributed to the scientific literature in both pathogenesis and 
treatment of leishmaniasis. 
The results of the laboratory based research have demonstrated that DC play an 
important role in establishing an early primary T cell response to L.major PM. DC 
internalise L.major PM with maximal expression of costimulatory and MHC Class II 
molecules and in response produce IL-12. Combined with results of the primary 
stimulation assays these findings suggest that DC from both susceptible and resistant 
mouse strains are able to stimulate autologous naive T cells when pulsed with PM 
antigens and provide a cytoldne environment predicted to favour the development of 
a Thl response. This work combined with the findings of other investigators has 
established the pivotal role of DC, rather than macrophages, in the early 
immunoregulation Of host response to murine cutaneous leishmaniasis. 
6.1 Human studies 
Research has begun to identify disease susceptibility and resistance factors in the 
human population (reviewed by Blackwell 1996). Not surprisingly, T cell and 
cytolcine responses in humans are more complex and less polarised than they are in 
inbred strains of mice. Nevertheless, the murine model of leishmaniasis has led to 
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several important observations in humans. There is a clear requirement for IFN-y to 
cure human disease, making IL-12 an attractive potential adjuvant for vaccination 
and therapy. Genetic susceptibility to different forms of leislunaniasis does appear to 
exist in humans and provides the basis for a relatively new area of intensive human 
research.. 
6.2 Future Perspectives 
The future in managing leishmaniasis is to develop vaccines using DC to treat and 
prevent the infection with the generation of long-lasting immunity. Protective effects 
have already been observed with some infections. DC pulsed with dead Chlamydia 
trachomatis, another intracellular pathogen, produced IL-12p40 and afforded 
protection to the female genital tract equivalent to that seen following live infection 
(Su, et al 1998). Similar protective effects have been observed after immunisation 
with microbe-pulsed DC in other models, including Borrelia burgdorferi (Mbow, et 
al 1997), murine lyrnphocytic choriomeningitis virus (Ludewig, et al 1998) and 
Toxoplasma (Bourguin, et al 1998). Heidrun Moll's group have also shown that 
susceptible mice could be protected against L.major infection following 
immunisation with L.major antigen pulsed LC. 
DC have also been used in genetic vaccination strategies. DC isolated from the skin 
of gp63-DNA vaccinated mice were able to induce protection against L.major in 
naïve recipients (Walker, et al 1998). Even more novel and exciting is genetic 
manipulation of DC, by retroviral transduction, to impart constitutive IL-12 
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production which then augments DC capacity to stimulate a response to Leishmania 
major in vitro (Ahuja, et al 1998). 
This study has also identified a potential role for DC in the search of non-peptide 
antigens shed by L.major which are presented via non-classical MHC pathways, as 
potential vaccine candidates. CD1 molecules have recently been shown to be 
involved in the presentation of lipoglycan, an antigen abundant on the surface of 
Leishmania promastigotes, to specific T cells (Porcelli and Modlin 1999). 
The challenge now lies in refining our understanding of the DC response to L.major 
pathogens in order to identify optimal conditions for antigen presentation by DC and 
development of effective vaccines which are safe and produce long lasting immunity. 
Extensive research has shown that different DC subsets can lead to different 
functional outcomes. These subsets require further definition. How DC process 
antigen, particularly whether they are able to control parasite replication and if so, by 
what mechanisms, is still relatively unexplored. The feedback mechanisms from 
lymphocytes and other APC to activated DC which may modulate DC surface 
molecule expression and cytoldne and chemokine production are as yet undefined. 
Such feedback could ultimately determine the nature of the adaptive immune 
response, particularly in determining whether tolerance or immunity develops. The 
role DC play in interacting and activating other APC in close proximity at the site of 
entry of the infectious parasite is also unexplored. The receptors and surface 
molecules involved in activation of the DC needs to be characterised as these may 
present molecular targets for the development of therapeutic interventions as well as 
antigens for DC vaccination research. 
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6.3 Concluding remarks 
Due to the degree of human suffering caused by leishmaniasis, a great need exists to 
translate the advances in the understanding of the immune response and the 
pathogenesis of leishmaniasis into effective, affordable and practical methods for 
treatment and prevention of this disease. Knowledge of the immunoregulatory 
mechanisms the host uses for control of infection will eventually lead to better 
treatments. This was highlighted in this manuscript where the observation that NO is 
required for intramacrophage killing of parasites was translated into the search for 
NO-generating local therapies. 
The conventional view that antigen processing and antigen presenting are relatively 
mutually exclusive functions of DC, depending on their degree of maturation, has 
been further challenged by this work. Delineation of DC subtypes with distinct 
characteristics and functions will provide a greater understanding of the role they 
play in the intricate intercellular interactions which determine disease outcomes. The 
studies performed in this thesis provide further evidence that DC play a critical and 
pivotal role in the pathogenesis of leishmaniasis. The development of the in vitro 
model used in this study has provided a valuable tool to further investigate antigen 
presentation in the immune response to leishmaniasis. Substitution of mast cells for 
DC in this model will allow study of the role of mast cells in leishmaniasis. Antigens 
derived from PM cultures can be assessed for their immunogenicity using this in 
vitro system, with a particular emphasis on non-peptide antigens and CD1 
presentation. Results of this work and proposed studies using this model will add to 
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the groundswell of research to ultimately develop cytokine and DC-directed 
strategies for future treatment and prevention of leishmaniasis. 
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